



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

1 6 October 2015
2 EMA/CPMP/ICH/2887/1999
3 Committee for Human Medicinal Products

4 **M4E(R2) - Common technical document for the**
5 **registration of pharmaceuticals for human use – Efficacy**
6 **Step 3**

7

Transmission to CHMP	August 2015
Adopted by CHMP for release for consultation	24 September 2015
Start of public consultation	7 October 2015
End of consultation (deadline for comments)	31 December 2015

8
9

Comments should be provided using this [template](#). The completed comments form should be sent to ich@ema.europa.eu

10



M4E(R1)

Document History

First Codification	History	Date	New Codification November 2005
M4E	Approval by the Steering Committee under <i>Step 2</i> and release for public consultation.	20 July 2000	M4E
M4E	Approval by the Steering Committee under <i>Step 4</i> and recommendation for adoption to the three ICH regulatory bodies.	8 November 2000	M4E

Step 4 version

M4E	Approval by the Steering Committee of Numbering and Section Headers changes for consistency directly under <i>Step 4</i> without further public consultation.	12 September 2002	M4E(R1)
-----	---	-------------------	---------

In order to facilitate the implementation of the M4E guideline, the ICH Experts have developed a series of Q&As which can be downloaded from the ICH web site: <http://www.ich.org>

M4E Questions & Answers History

M4E Q&As	Approval by the Steering Committee.	11 February 2002	M4E Q&As
M4E Q&As	Approval by the Steering Committee of the newly added questions.	12 September 2002	M4E Q&As (R1)
M4E Q&As	Approval by the Steering Committee of the newly added questions.	6 February 2003	M4E Q&As (R2)
M4E Q&As	Approval by the Steering Committee of the newly added questions.	11 November 2003	M4E Q&As (R3)

M4E Questions & Answers posted on the web site

M4E Q&As	Approval by the Steering Committee of the newly added questions.	10 June 2004	M4E Q&As (R4)
----------	--	--------------	---------------

Current Step 2 version of the M4E(R2)

M4E(R2)	Approval by the Steering Committee under <i>Step 2b</i> and release for public consultation. Only the guideline for Sections 2.5.1 and 2.5.6 has been revised.	5 August 2015
---------	--	---------------

21 ICH guideline M4E(R2) - Common technical document for
22 the registration of pharmaceuticals for human use –
23 Efficacy
24 Step 3

25 **Table of contents**

26 **Module 2: common technical document summaries..... 4**

27 2.5 Clinical overview4

28 Preamble4

29 Table of contents5

30 Detailed discussion of content of the clinical overview sections5

31 2.5.1 Product development rationale5

32 2.5.2 Overview of biopharmaceutics.....6

33 2.5.3 Overview of clinical pharmacology6

34 2.5.4 Overview of efficacy6

35 2.5.5 Overview of safety.....7

36 2.5.6 Benefits and risks conclusions8

37 2.5.7 Literature references..... 13

38 2.7 Clinical summary..... 13

39 Preamble 13

40 Table of Contents..... 14

41 Detailed guidance on sections of the clinical summary 15

42 2.7.1 Summary of biopharmaceutic Studies and associated analytical methods 15

43 2.7.2 Summary of clinical pharmacology studies..... 16

44 2.7.3 Summary of clinical efficacy..... 19

45 2.7.4 Summary of clinical safety 23

46 2.7.5 Literature references..... 32

47 2.7.6 Synopses of individual studies..... 32

48 **Module 5: clinical study reports..... 46**

49 Preamble 46

50 Detailed organisation of clinical study reports and related information in module 5..... 46

51 5.1 Table of contents of module 5..... 46

52 5.2 Tabular listing of all clinical studies..... 47

53 5.3 Clinical study reports 47

54 5.3.1 Reports of biopharmaceutic studies..... 47

55 5.3.2 Reports of studies pertinent to pharmacokinetics using human biomaterials..... 48

56 5.3.4 Reports of human pharmacodynamic (PD) studies 50

57 5.3.5 Reports of efficacy and safety studies 51

58 5.3.6 Reports of post-marketing experience 52

59 5.3.7 Case report forms and individual patient listings..... 52

60 5.4 Literature references 52

Module 2: common technical document summaries

2.5 Clinical overview

Preamble

The Clinical Overview is intended to provide a critical analysis of the clinical data in the Common Technical Document. The Clinical Overview will necessarily refer to application data provided in the comprehensive Clinical Summary, the individual clinical study reports (ICH E3), and other relevant reports; but it should primarily present the conclusions and implications of those data, and should not recapitulate them. Specifically, the Clinical Summary should provide a detailed factual summarisation of the clinical information in the CTD, and the Clinical Overview should provide a succinct discussion and interpretation of these findings together with any other relevant information (e.g., pertinent animal data or product quality issues that may have clinical implications).

The Clinical Overview is primarily intended for use by regulatory agencies in the review of the clinical section of a marketing application. It should also be a useful reference to the overall clinical findings for regulatory agency staff involved in the review of other sections of the marketing application. The Clinical Overview should present the strengths and limitations of the development program and study results, analyse the benefits and risks of the medicinal product in its intended use, and describe how the study results support critical parts of the prescribing information.

In order to achieve these objectives the Clinical Overview should:

- describe and explain the overall approach to the clinical development of a medicinal product, including critical study design decisions.
- assess the quality of the design and performance of the studies, and include a statement regarding GCP compliance.
- provide a brief overview of the clinical findings, including important limitations (e.g., lack of comparisons with an especially relevant active comparator, or absence of information on some patient populations, on pertinent endpoints, or on use in combination therapy).
- provide an evaluation of benefits and risks based upon the conclusions of the relevant clinical studies, including interpretation of how the efficacy and safety findings support the proposed dose and target indication and an evaluation of how prescribing information and other approaches will optimise benefits and manage risks.
- address particular efficacy or safety issues encountered in development, and how they have been evaluated and resolved.
- explore unresolved issues, explain why they should not be considered as barriers to approval, and describe plans to resolve them.
- explain the basis for important or unusual aspects of the prescribing information.

The Clinical Overview should generally be a relatively short document (about 30 pages). The length, however, will depend on the complexity of the application. The use of graphs and concise tables in the body of the text is encouraged for brevity and to facilitate understanding. It is not intended that material presented fully elsewhere be repeated in the Clinical Overview; cross-referencing to more detailed presentations provided in the Clinical Summary or in Module 5 is encouraged.

100 **Table of contents**

101 2.5.1 Product Development Rationale

102 2.5.2 Overview of Biopharmaceutics

103 2.5.3 Overview of Clinical Pharmacology

104 2.5.4 Overview of Efficacy

105 2.5.5 Overview of Safety

106 2.5.6 Benefits and Risks Conclusions

107 2.5.6.1 Therapeutic Context

108 2.5.6.1.1 Disease or Condition

109 2.5.6.1.2 Current Therapies

110 2.5.6.2 Benefits

111 2.5.6.3 Risks

112 2.5.6.4 Benefit-Risk Assessment

113 2.5.6.5 Appendix

114 2.5.7 Literature References

115 **Detailed discussion of content of the clinical overview sections**

116 **2.5.1 Product development rationale**

117 The discussion of the rationale for the development of the medicinal product should:

- 118 • identify the pharmacological class of the medicinal product.
- 119 • describe the particular clinical/pathophysiological condition that the medicinal product is intended
120 to treat, prevent, or diagnose (the targeted indication).
- 121 • include a brief overview of the major therapies currently used in the intended population and how
122 they influenced product development.
- 123 • briefly summarise the scientific background that supported the investigation of the medicinal
124 product for the indication(s) that was (were) studied.
- 125 • briefly describe the clinical development programme of the medicinal product, including ongoing
126 and planned clinical studies and the basis for the decision to submit the application at this point in
127 the programme. Briefly describe plans for the use of foreign clinical data (ICH E5).

128 note and explain concordance or lack of concordance with current standard research approaches
129 regarding the design, conduct and analysis of the studies. Pertinent published literature should be
130 referenced. Regulatory guidance and advice (at least from the region(s) where the Clinical Overview is
131 being submitted) should be identified, with discussion of how that advice was implemented. Formal
132 advice documents (e.g., official meeting minutes, official guidance, letters from regulatory authorities)
133 should be referenced, with copies included in the references section of Module 5.

2.5.2 Overview of biopharmaceutics

The purpose of this section is to present a critical analysis of any important issues related to bioavailability that might affect efficacy and/or safety of the to-be-marketed formulation(s) (e.g., dosage form/strength proportionality, differences between the to-be-marketed formulation and the formulation(s) used in clinical trials, and influence of food on exposure).

2.5.3 Overview of clinical pharmacology

The purpose of this section is to present a critical analysis of the pharmacokinetic (PK), pharmacodynamic (PD), and related *in vitro* data in the CTD. The analysis should consider all relevant data and explain why and how the data support the conclusions drawn. It should emphasise unusual results and known or potential problems, or note the lack thereof. This section should address:

- pharmacokinetics, e.g., comparative PK in healthy subjects, patients, and special populations; PK related to intrinsic factors (e.g., age, sex, race, renal and hepatic impairment) and to extrinsic factors (e.g., smoking, concomitant drugs, diet); rate and extent of absorption; distribution, including binding with plasma proteins; specific metabolic pathways, including effects of possible genetic polymorphism and the formation of active and inactive metabolites; excretion; time-dependent changes in pharmacokinetics; stereochemistry issues; clinically relevant PK interactions with other medicinal products or other substances.
- pharmacodynamics, e.g., information on mechanism of action, such as receptor binding; onset and/or offset of action; relationship of favorable and unfavorable pharmacodynamic effects to dose or plasma concentration (i.e., PK/PD relationships); PD support for the proposed dose and dosing interval; clinically relevant PD interactions with other medicinal products or substances; and possible genetic differences in response.
- interpretation of the results and implications of immunogenicity studies, clinical microbiology studies, or other drug class specific PD studies summarised in section 2.7.2.4 of the Clinical Summary.

2.5.4 Overview of efficacy

The purpose of this section is to present a critical analysis of the clinical data pertinent to the efficacy of the medicinal product in the intended population. The analysis should consider all relevant data, whether positive or negative, and should explain why and how the data support the proposed indication and prescribing information. Those studies deemed relevant for evaluation of efficacy should be identified, and reasons that any apparently adequate and well-controlled studies are not considered relevant should be provided. Prematurely terminated studies should be noted and their impact considered.

The following issues should generally be considered:

- relevant features of the patient populations, including demographic features, disease stage, any other potentially important covariates, any important patient populations excluded from critical studies, and participation of children and elderly (ICH E11 and E7). Differences between the studied population(s) and the population that would be expected to receive the medicinal product after marketing should be discussed.

- implications of the study design(s), including selection of patients, duration of studies and choice of endpoints and control group(s). Particular attention should be given to endpoints for which there is limited experience. Use of surrogate endpoints should be justified. Validation of any scales used should be discussed.
- for non-inferiority trials used to demonstrate efficacy, the evidence supporting a determination that the trial had assay sensitivity and justifying the choice of non-inferiority margin (ICH E10).
- statistical methods and any issues that could affect the interpretation of the study results (e.g., important modifications to the study design, including endpoint assessments and planned analyses, as they were specified in the original protocol; support for any unplanned analyses; procedures for handling missing data; and corrections for multiple endpoints).
- similarities and differences in results among studies, or in different patient sub-groups within studies, and their effect upon the interpretation of the efficacy data.
- observed relationships between efficacy, dose, and dosage regimen for each indication, in both the overall population and in the different patient subgroups (ICH E4).
- support for the applicability to the new region of data generated in another region, where appropriate (ICH E5).
- for products intended for long-term use, efficacy findings pertinent to the maintenance of long-term efficacy and the establishment of long-term dosage. Development of tolerance should be considered.
- data suggesting that treatment results can be improved through plasma concentration monitoring, if any, and documentation for an optimal plasma concentration range.
- the clinical relevance of the magnitude of the observed effects.
- if surrogate endpoints are relied upon, the nature and magnitude of expected clinical benefit and the basis for these expectations.
- efficacy in special populations. If efficacy is claimed with inadequate clinical data in the population, support should be provided for extrapolating efficacy from effects in the general population.

2.5.5 Overview of safety

The purpose of this section is to provide a concise critical analysis of the safety data, noting how results support and justify proposed prescribing information. A critical analysis of safety should consider:

- adverse effects characteristic of the pharmacological class. Approaches taken to monitor for similar effects should be described.
- special approaches to monitoring for particular adverse events (e.g., ophthalmic, QT interval prolongation).
- relevant animal toxicology and product quality information. Findings that affect or could affect the evaluation of safety in clinical use should be considered.
- the nature of the patient population and the extent of exposure, both for test drug and control treatments. Limitations of the safety database, e.g., related to inclusion/exclusion criteria and

study subject demographics, should be considered, and the implications of such limitations with respect to predicting the safety of the product in the marketplace should be explicitly discussed.

- common and non-serious adverse events, with reference to the tabular presentations of events with the test drug and with control agents in the Clinical Summary. The discussion should be brief, focusing on events of relatively high frequency, those with an incidence higher than placebo, and those that are known to occur in active controls or other members of the therapeutic class. Events that are substantially more or less common or problematic (considering the duration and degree of the observed events) with the test drug than with active controls are of particular interest.
- serious adverse events (relevant tabulations should be cross-referenced from the Clinical Summary). This section should discuss the absolute number and frequency of serious adverse events, including deaths, and other significant adverse events (e.g., events leading to discontinuation or dose modification), and should discuss the results obtained for test drug versus control treatments. Any conclusions regarding causal relationship (or lack of this) to the product should be provided. Laboratory findings reflecting actual or possible serious medical effects should be considered.
- similarities and differences in results among studies, and their effect upon the interpretation of the safety data.
- any differences in rates of adverse events in population subgroups, such as those defined by demographic factors, weight, concomitant illness, concomitant therapy, or polymorphic metabolism.
- relation of adverse events to dose, dose regimen, and treatment duration.
- long-term safety (E1a).
- methods to prevent, mitigate, or manage adverse events.
- reactions due to overdose; the potential for dependence, rebound phenomena and abuse, or lack of data on these issues.
- world-wide marketing experience. The following should be briefly discussed:
 - the extent of the world-wide experience,
 - any new or different safety issues identified,
 - any regulatory actions related to safety.
- support for the applicability to the new region of data generated in another region, where appropriate (ICH E5).

2.5.6 Benefits and risks conclusions

Preamble

The purpose of this section is to provide a succinct, integrated, and clearly explained benefit-risk assessment of the medicinal product for its intended use. This assessment should include any important strengths, limitations, and uncertainties in the available data. Some of the expected information in Section 2.5.6 as described below may be adequately addressed in other parts of the application and should not be reiterated here in detail. In such cases, the applicant should use cross-references to more detailed presentations provided elsewhere in the application. The content of each

subsection should provide the applicant's conclusions with a clear explanation of the reasoning behind the analysis and the thought process that led to the conclusions.

Section 2.5.6 represents the first benefit-risk assessment of a medicinal product in the proposed indication submitted to a regulatory authority. This assessment is based on a weighing of the key benefits and key risks of the medicinal product—those that contribute importantly to the benefit-risk assessment—and do not necessarily include all benefits and risks. The identification of the key benefits and key risks of a product requires a critical review of the entirety of the efficacy and safety information relevant for the application. Subsequent benefit-risk assessments of approved products are the subject of the ICH E2C(R2) (Periodic Benefit-Risk Evaluation Report: PBRER) guideline, which similarly uses the concepts of key benefits and key risks.

The following additional points should be considered when completing this section:

- Multiple indications: If multiple indications are proposed for the medicinal product, each indication may be supported by a separate section heading where appropriate. For example, it may be sensible to separate the discussion of therapeutic context, benefit, and the benefit-risk assessment for different indications, whereas the discussion of risk may be combined. Where indications are discussed separately, a separate section should be provided for each indication using headings, e.g., 2.5.6.1 Pneumonia and 2.5.6.1 Upper Respiratory Infection. When indications are closely related, the applicant may consider discussing them together in the appropriate sections.
- In some cases, a certain characteristic of the medicinal product may reasonably be described under benefits or risks. For example, the medicinal product may exhibit an improved safety profile over existing treatment, a reduced risk (e.g., fractures in osteoporosis), or may show reduced efficacy over time. Whether such considerations are discussed as benefits or as risks is a decision for the applicant, but they should not be discussed as both.
- Available information about the patient perspective¹ may be considered when completing Section 2.5.6.
- Tables or figures may be included in Section 2.5.6 to support or provide greater clarity to key points or conclusions.

2.5.6.1 Therapeutic context

This section should briefly discuss the therapeutic context for the purpose of describing the medical need for a new medicinal product. The therapeutic context includes the disease or condition and the benefits and risks of current therapies that are most relevant to the evaluation of the medicinal product in the intended population. Significant limitations or uncertainties in the understanding of the condition or therapies should be discussed. Information about disease severity in subpopulations should be provided as it relates to differences in how the therapeutic context may be considered in the benefit-risk assessment for those populations. The discussion may be brief if the condition and treatment options are well understood. This section should not include information on the benefits and risks of the applicant's medicinal product; this information should be discussed in Sections 2.5.6.2 and 2.5.6.3.

¹ Patient perspective information encompasses descriptive information of patient attitudes regarding aspects covered in this section, as well as information obtained from methodologies intended to elicit the patient perspective (e.g., patient preference studies). If such studies are submitted, the detailed study reports may be submitted to Module 5.

2.5.6.1.1 Disease or condition

This section provides a description of aspects of the disease or condition that are most relevant to, or have the greatest impact on, the intended population (e.g., incidence, duration, morbidity, mortality, health-related quality of life) across the spectrum of disease severity. The discussion may begin from a broad perspective of the disease and then should focus on the aspects of the disease that would be covered by the proposed indication for the medicinal product. Societal or public health implications of the condition (e.g., impact of poor control and prevention of an infectious disease) should also be addressed where relevant.

2.5.6.1.2 Current therapies²

This section provides a description of the major therapies in the intended population (i.e., those therapies used most frequently and/or recommended in clinical guidelines) and the medical need for a new therapy in terms of efficacy, safety, tolerability, convenience, or preference, if applicable. For disease areas that are treated by different pharmacologic classes of therapies, this analysis may be simplified by grouping and providing commentary by drug class. Other interventions used for the intended population may also be discussed when their use is supported by established clinical practice. Such interventions could include medical and surgical procedures, drugs used off-label, and other non-drug interventions (e.g., diet modifications, physical therapy). Major differences in current therapies between regions may be noted. If no therapies are currently available to treat the indication, this should be stated.

2.5.6.2 Benefits

This section summarizes the key benefits that will be discussed in the benefit-risk assessment of the medicinal product. Benefits can be thought of as the favorable effects of the medicinal product. Typically, a benefit is described by the primary efficacy endpoint. In some cases, a benefit may be described by a combination of individual study endpoints, e.g., the benefit of improved asthma control described by the frequency of exacerbations and hospitalizations and the number of asthma-related deaths. Benefits may also include important characteristics of the medicinal product, including its convenience (e.g., a more convenient dosing regimen or route of administration) that may lead to improved patient compliance or benefits that affect those other than the patient (e.g., population benefits of a vaccine due to herd immunity).

The following characteristics may be considered when identifying the key benefits of the medicinal product:

- nature of benefit (e.g., life-prolonging, curative, disease-modifying, symptomatic relief, improved patient compliance, functional or quality of life improvement, preventive, or diagnostic);
- clinical importance of the benefit (e.g., less frequent hospitalization, prevention of disease progression);
- absolute difference in effect versus comparator; in some cases, also expressing the difference in relative terms can inform the assessment of benefit

² For purposes of this section, the term "therapy" encompasses both pharmacologic and non-pharmacologic interventions, as well as preventive measures and diagnostics. In addition, the terms "therapy" and "treatment" are used interchangeably.

In addition to the points above, the following considerations may also be discussed when describing each key benefit:

- time course of the key benefit (e.g., time to onset, continued effect of the medicinal product over time);
- variability of the key benefit across the study population, particularly in important subpopulations (e.g., those defined by age, sex, ethnicity, organ function, disease severity, genetic polymorphism)

This section should also include an analysis of the strengths, limitations, and uncertainties of the evidence related to each key benefit and the implications of this information. The following points may be considered, as applicable:

- study design considerations (e.g., superiority or non-inferiority comparison to active control, superiority comparison to placebo, blinding, absence of comparator);
- data analysis considerations (e.g., patient retention, missing data);
- number of clinical studies and consistency of results across studies;
- relationship between dose or exposure (e.g., drug levels in the blood) and benefit;
- generalizability of the clinical study data to clinical practice (e.g., clinically important differences between the study population and the intended population);
- confidence that surrogate endpoints, if used, predict that the intended population will receive the benefits.

2.5.6.3 Risks

This section summarizes the key risks that will be discussed in the benefit-risk assessment of the medicinal product. Risk is sometimes used to refer to a particular adverse effect (e.g., an adverse drug reaction) that can be caused by a medicinal product. However, the term is used here to refer to the frequency and severity of an unfavorable effect associated with the medicinal product, including the seriousness of the outcomes of the risk and its potential impact on public health. The key risks described in this section may not include all important risks that are described elsewhere in the application (e.g., risk management plan). For important risks that are not identified as key risks, the applicant should explain these selections.

This section should also consider important adverse drug reactions that affect certain subpopulations, drug interactions, unique risks compared to existing therapies, risks identified in the non-clinical data, risks to those other than the patient (e.g., fetus, those administering the medicinal product), and expected risks based on pharmacologic class or current knowledge of the product's safety if previously approved. Factors that may increase risk, such as misuse or abuse of the product, should also be considered.

The following characteristics of adverse drug reactions may be considered when identifying the key risks of the medicinal product:

- seriousness and/or severity of the adverse drug reaction;
- frequency of the adverse drug reaction in the study population versus the comparator(s) and/or the background rate in the patient population;
- reversibility of the adverse drug reaction;

- 364 • tolerability of the adverse drug reaction, e.g., whether they lead to discontinuation of therapy.
- 365 In addition to the points above, the following considerations may also be discussed when describing
366 each key risk:
- 367 • ability to predict, prevent, monitor, or manage the adverse drug reaction;
- 368 • time course of the adverse drug reaction in the study population (i.e., time to onset, whether the
369 frequency of the event is highest when initiating the drug and subsequently decreases, is relatively
370 constant with time, or increases with cumulative exposure).

371 This section should also include an analysis of the strengths, limitations, and uncertainties regarding
372 the relevant safety information. The following points may be considered, as applicable:

- 373 • adequacy of assessment of risk (e.g., number of patients, number and design of trials, duration of
374 exposure, frequency of monitoring, or the conduct of special studies to assess risk such as QTc
375 effect studies);
- 376 • duration and completeness of follow-up;
- 377 • number of patients in relevant subpopulations treated at the intended dose;
- 378 • mechanism of action for the adverse drug reaction, if known, including non-clinical information or
379 class effects;
- 380 • completeness of information on relevant risk factors associated with observed adverse events in
381 trial subjects (e.g., baseline smoking history, concomitant medication use);
- 382 • consistency of results across studies;
- 383 • relationship between dose or exposure (e.g., drug levels in the blood) and risk;
- 384 • limitations on the ability to generalize clinical study data to clinical practice (e.g., clinically
385 important differences between the study population and the intended population) .

386 The proposed approach to managing each key risk should also be discussed, including an explanation
387 of why the approach provides reasonable assurance that the risk can be appropriately managed.
388 Repetition of details from the Risk Management Plan is not necessary. In certain cases, a discussion of
389 the overall approach to risk management may be sufficient and may be included after all key risks
390 have been identified and described.

391 **2.5.6.4 Benefit-risk assessment**

392 This section should provide the applicant's conclusion on the benefit-risk assessment, including a
393 succinct explanation of the reasoning and clinical judgment used in assessing and weighing the key
394 benefits and key risks. In addition, the applicant should explain how any uncertainties affect the
395 interpretation of the evidence and the conclusion. Although previous parts of Section 2.5.6 focus on
396 factual descriptions of the data, the benefit-risk assessment should focus on interpretation of the data.

397 There are many approaches available for conducting the benefit-risk assessment. A descriptive
398 approach that explicitly communicates the interpretation of the data and the benefit-risk assessment
399 will generally be adequate. Beyond this, the guideline does not prescribe a specific methodology.
400 However, an applicant may choose to use methodologies that quantitatively express the underlying
401 judgments and uncertainties in the assessment. Before using such methodology, the applicant should
402 consider its utility, complexity, the extent to which the methodology is established, and the ease of

interpretation of the results. In this situation, a written summary and explanation of the conclusions should still be provided in this section. The detailed presentation of the methodology should be appended in Section 2.5.6.5.

Applicants may, at their discretion, use summary tables or graphical displays to communicate the clinical importance of the key benefits and key risks, as well as the resulting benefit-risk assessment.

The following aspects should generally be considered when describing the benefit-risk assessment:

- The impact of the therapeutic context on the assessment, including how the severity of disease and expected benefit influence the acceptance of the risks of the therapy and how the medicinal product is expected to fit with current treatment options. This discussion may be supported by available information about patient perspectives;
- The ability of the patient or healthcare provider to determine if the drug is having the intended effect, allowing for appropriate risk mitigation by discontinuing treatment in non-responders;
- Key aspects of the proposed labeling and risk management activities that are important in reaching a favorable benefit-risk assessment

2.5.6.5 Appendix

Lengthy reports of a benefit-risk assessment that are summarized in Section 2.5.6.4 can be provided in this section.

2.5.7 Literature references

A list of references used, stated in accordance with the current edition of the *Uniform Requirements for Manuscripts Submitted to Biomedical Journals*, International Committee of Medical Journal Editors (ICMJE)³ or the system used in "Chemical Abstracts", should be provided. Copies of all references cited in the Clinical Overview should be provided in Section 5.4 of Module 5.

2.7 Clinical summary

Preamble

The Clinical Summary is intended to provide a detailed, factual summarisation of all of the clinical information in the Common Technical Document. This includes information provided in ICH E3 clinical study reports; information obtained from any meta-analyses or other cross-study analyses for which full reports have been included in Module 5; and post-marketing data for products that have been marketed in other regions. The comparisons and analyses of results across studies provided in this document should focus on factual observations. In contrast, the CTD Clinical Overview document should provide critical analysis of the clinical study program and its results, including discussion and interpretation of the clinical findings and discussion of the place of the test drug in the armamentarium.

The length of the Clinical Summary will vary substantially according to the information to be conveyed, but it is anticipated that (excluding attached tables) the Clinical Summary will usually be in the range of 50 to 400 pages.

³ The first edition of the *Uniform Requirements for Manuscripts Submitted to Biomedical Journals* was conceived by the Vancouver Group and was published in 1979.

439	Table of Contents
440	2.7.1 Summary of Biopharmaceutic Studies and Associated Analytical Methods
441	2.7.1.1 Background and Overview
442	2.7.1.2 Summary of Results of Individual Studies
443	2.7.1.3 Comparison and Analyses of Results Across Studies
444	2.7.1.4 Appendix
445	2.7.2 Summary of Clinical Pharmacology Studies
446	2.7.2.1 Background and Overview
447	2.7.2.2 Summary of Results of Individual Studies
448	2.7.2.3 Comparison and Analyses of Results Across Studies
449	2.7.2.4 Special Studies
450	2.7.2.5 Appendix
451	2.7.3 Summary of Clinical Efficacy
452	2.7.3.1 Background and Overview of Clinical Efficacy
453	2.7.3.2 Summary of Results of Individual Studies
454	2.7.3.3 Comparison and Analyses of Results Across Studies
455	2.7.3.4 Analysis of Clinical Information Relevant to Dosing Recommendations
456	2.7.3.5 Persistence of Efficacy and/or Tolerance Effects
457	2.7.3.6 Appendix
458	2.7.4 Summary of Clinical Safety
459	2.7.4.1 Exposure to the Drug
460	2.7.4.2 Adverse Events
461	2.7.4.3 Clinical Laboratory Evaluations
462	2.7.4.4 Vital Signs, Physical Findings, and Other Observations Related to Safety
463	2.7.4.5 Safety in Special Groups and Situations
464	2.7.4.6 Post-marketing Data
465	2.7.4.7 Appendix
466	2.7.5 Literature References
467	2.7.6 Synopses of Individual Studies

Detailed guidance on sections of the clinical summary

2.7.1 Summary of biopharmaceutic Studies and associated analytical methods

2.7.1.1 Background and Overview

This section should provide the reviewer with an overall view of the formulation development process, the *in vitro* and *in vivo* dosage form performance, and the general approach and rationale used in developing the bioavailability (BA), comparative BA, bioequivalence (BE), and *in vitro* dissolution profile database. Reference should be made to any guidelines or literature used in planning and conducting the studies. This section should also provide the reviewer with an overview of the analytical methods used, with emphasis on the performance characteristics of assay validation (e.g., linearity range, sensitivity, specificity) and quality control (e.g., accuracy and precision). This section should not include detailed information about individual studies.

2.7.1.2 Summary of results of individual studies

A tabular listing of all biopharmaceutic studies should generally be provided (see 2.7.1.4 Appendix), together with narrative descriptions of relevant features and outcomes of each of the individual studies that provided important *in vitro* or *in vivo* data and information relevant to BA and BE. The narrative descriptions should be brief, e.g., similar to an abstract for a journal article, and should describe critical design features and critical results. Similar studies may be described together, noting the individual study results and any important differences among the studies. These narratives may be abstracted from the ICH E3 synopsis. References or electronic links to the full report of each study should be included in the narratives.

2.7.1.3 Comparison and analyses of results across studies

This section should provide a factual summary of all *in vitro* dissolution, BA, and comparative BA studies carried out with the drug substance or drug product, with particular attention to differences in results across studies. This overview should typically summarise the findings in text and tables (see 2.7.1.4 Appendix) and should consider the following:

- evidence of the effects of formulation and manufacturing changes on *in vitro* dissolution and BA and conclusions regarding BE. When manufacturing or formulation changes are made for products containing complex drug substances (e.g., a protein), pharmacokinetic (PK) studies comparing the product before and after the changes may be performed to ensure that the PK characteristics have not changed as a result of product changes. Although such studies are sometimes referred to as BE studies, they generally do not focus on assessing release of drug substance from drug product. Nonetheless, such studies should be reported in this section. Note also that PK studies alone may not be sufficient to assure similarity between such drug products. In many situations, pharmacodynamic (PD) studies or clinical trials may be necessary. Additionally, depending on the circumstances, antigenicity data may also be needed. Results of these other types of studies, when they are needed, should be reported in the appropriate places in the dossier.
- evidence of the extent of food effects on BA and conclusions regarding BE with respect to meal type or timing of the meal (where appropriate).
- evidence of correlations between *in vitro* dissolution and BA, including the effects of pH on dissolution, and conclusions regarding dissolution specifications.

- comparative bioavailability, including BE conclusions, for different dosage form strengths.
- comparative BA of the clinical study formulations (for clinical studies providing substantial evidence of efficacy) and the formulations to be marketed.
- the source and magnitude of observed inter- and intrasubject variability for each formulation in a comparative BA study.

2.7.1.4 Appendix

Tables and figures should be embedded in the text of the appropriate sections when they enhance the readability of the document. Lengthy tables can be provided in the appendix at the end of the Section.

Tables 2.7.1.1 and 2.7.1.2 are provided as examples of tabular formats for reporting information and results related to bioavailability and *in vitro* dissolution studies respectively. These examples give results as well as identifying the type and design of the study. Tables prepared for reporting the results of BE studies could also include the mean ratios (test/reference) for C_{max} and AUC and their 90% confidence interval, or the currently recommended metrics for BE assessments.

These tables are not intended to be templates, but only to illustrate the type of information that should be considered by an applicant in designing the tables for biopharmaceutic studies. Applicants should also decide whether information and results from these studies are best presented in tables, text or figures in order to aid clarity. If, for example, results are best presented in text and figures, tables might be used simply to list the studies.

2.7.2 Summary of clinical pharmacology studies

2.7.2.1 Background and overview

This section should provide the reviewer with an overall view of the clinical pharmacology studies. These studies include clinical studies performed to evaluate human pharmacokinetics (PK), and pharmacodynamics (PD), and *in vitro* studies performed with human cells, tissues, or related materials (hereinafter referred to as human biomaterials) that are pertinent to PK processes. For vaccine products, this section should provide the reviewer with immune response data that support the selection of dose, dosage schedule, and formulation of the final product. Where appropriate, relevant data that are summarised in sections 2.7.1, 2.7.3 and 2.7.4 can also be referenced to provide a comprehensive view of the approach and rationale for the development of the pharmacokinetic, pharmacodynamic, PK/PD and human biomaterial database. This section should not include detailed information about individual studies.

This section should begin with a brief overview of the human biomaterial studies that were conducted and that were intended to help in the interpretation of PK or PD data. Studies of permeability (e.g., intestinal absorption, blood brain barrier passage), protein binding, hepatic metabolism, and metabolic-based drug-drug interactions are particularly relevant. This should be followed by a brief overview of the clinical studies that were carried out to characterise PK and PD of the medicinal product, including studies of PK/PD relationships in healthy subjects and patients, and relevant effects of intrinsic and extrinsic factors on PK and PK/PD relationships⁴. Critical aspects of study design and data analysis should be noted, e.g., the choice of the single or multiple doses used, the study population, choice of the intrinsic or extrinsic factors that were studied, the choice of PD endpoints,

⁴ In the ICH E5 guideline on Ethnic Factors in the Acceptance of Foreign Data, factors that may result in different responses to a drug in different populations are categorized as intrinsic ethnic factors or extrinsic ethnic factors. In this document, these categories are referred to as intrinsic factors and extrinsic factors, respectively.

and whether a traditional approach or a population approach was used to collect and analyse data to assess PK or PD.

2.7.2.2 Summary of results of individual studies

A tabular listing of all clinical pharmacology studies should generally be provided (see 2.7.2.5 Appendix), together with a narrative description of the relevant features and outcomes of each of the critical individual studies that provided in vitro or in vivo data and information relevant to PK, PD and PK/PD relationships. The narrative descriptions should be brief, e.g., similar to an abstract for a journal article, and should describe critical design features and critical results. Similar studies may be described together, noting the individual study results and any important differences among the studies. References or electronic links to the full report of each study should be included in the narratives.

Summaries of dose-response or concentration response (PK/PD) studies with pharmacodynamic endpoints should generally be included in this section. In some cases, however, when well-controlled dose-response PD or PK/PD studies provide important evidence of efficacy or safety, they should be placed in 2.7.3 or 2.7.4 as appropriate and referenced, but not summarised, here.

2.7.2.3 Comparison and analyses of results across studies

This section should use the results of all in vitro human biomaterial studies and PK, PD and PK/PD studies to characterise the PK, PD and PK/PD relationships of the drug. Results related to the inter- and intra-individual variability in these data and the intrinsic and extrinsic factors affecting these pharmacokinetic relationships should be discussed.

This section (typically with the use of text and tables) should provide a factual presentation of all data across studies pertinent to the following:

- in vitro drug metabolism and in vitro drug-drug interaction studies and their clinical implications.
- human PK studies, including the best estimates of standard parameters and sources of variability. The focus should be on evidence supporting dose and dose individualisation in the target patient population and in special populations, e.g., paediatric or geriatric patients, or patients with renal or hepatic impairment.
- comparison between single and repeated-dose PK
- population PK analyses, such as results based on sparse sampling across studies that address inter-individual variations in the PK or PD of the active drug substances that may be due to extrinsic or intrinsic factors.
- dose-response or concentration-response relationships. This discussion should highlight evidence to support the selection of dosages and dose intervals studied in the important clinical trials. In addition, information that supports the dosage instructions in the proposed labelling should be discussed in Section 2.7.3.4.
- major inconsistencies in the human biomaterial, PK, or PD database.
- PK studies that were performed to determine whether foreign clinical data could be extrapolated to the new region (see ICH E5). The result of the studies and analysis of the similarity of the PK data between regions or races should be summarised in this section. Such studies that use PD

biomarkers (but do not evaluate clinical efficacy) may similarly be summarised here. An independent subsection can be created to summarise these kinds of data.

2.7.2.4 Special studies

This section should include studies that provide special types of data relevant to specific types of medicinal products. For immunogenicity studies and other studies in which data may correlate with PK, PD, safety, and/or efficacy data, explanations of such correlations should be summarised here. Any observed or potential effects on PK, PD, safety and/or efficacy should be considered in other appropriate sections of the Clinical Summary as well, with cross-referencing to this section. Human studies that address a specific safety issue should not be reported here, but instead should be reported in the Summary of Clinical Safety (section 2.7.4).

Example 1: Immunogenicity

For protein products and other products to which specific immunological reactions have been measured, data regarding immunogenicity should be summarised in this section. For vaccines or other products intended to induce specific immune reactions, immunogenicity data should be described in the efficacy section 2.7.3. Assays used should be briefly described and information about their performance (e.g., sensitivity, specificity, reliability, validity) should be summarised; the location in the application of detailed information should be cross-referenced.

Data regarding the incidence, titre, timing of onset and duration of antibody responses should be summarised for each type of antibody assay used (e.g., IgG by ELISA, neutralisation). Relationships of antibody formation to underlying disease, concomitant medication, dose, duration, regimen, and formulation should be explored and summarised. For drugs intended to be given as chronic, continuous therapy, any data on the impact of interruptions of therapy on antigenicity should be analysed and summarised.

It is particularly important to summarise analyses of potential clinically relevant correlates of immunogenicity, e.g., to determine the extent to which the presence of antibodies of a particular type or titer appears to correlate with alterations of PK, changes in PD, loss of efficacy, loss of adverse event profile, or development of adverse events. Particular attention should be paid to events that might be immunologically mediated (e.g., serum sickness) and events that might result from binding of cross-reactive endogenous substances by antibodies to the administered drug.

Example 2: Clinical microbiology

For antimicrobial or antiviral medicinal products, *in vitro* studies to characterise the spectrum of activity are an important part of the programme of studies relevant to clinical efficacy. Clinical efficacy studies that include characterisation of the susceptibility of the clinical isolates as a part of the efficacy determination should be included in Section 2.7.3, Summary of Clinical Efficacy. However, studies that evaluate such findings as the pattern of *in vitro* susceptibility of strains of bacteria from different parts of the world (not in the context of clinical efficacy study) would be included here.

2.7.2.5 Appendix

Tables and figures should be embedded in the text of the appropriate sections when that enhances the readability of the document. Lengthy tables can be provided in the appendix at the end of the Section.

Table 2.7.2.1 is provided as an example of a tabular format for reporting information and results related to pharmacokinetic drug-drug interaction studies. Similar tables could be prepared for PK/PD

studies, dose-response studies, studies of effects on human biomaterials, and population PK studies. This table is not intended to be a template, but only to illustrate the type of information that should be considered by sponsors in designing their own tables. Applicants should also decide whether information and results from clinical pharmacology studies are best presented in tables, text or figures in order to aid clarity. If, for example, results are best presented in text and figures, the tables might simply list the studies.

In designing tables, if any, for various types of other clinical pharmacology studies such as those listed below, applicants should consider including the following types of information. These examples are for illustrative purposes only and the sponsor should decide which information needs to be presented.

- metabolism studies using human biomaterials: biomaterials used (e.g., microsomes, hepatocytes), probe drugs, enzymatic pathways and % contribution and relevant kinetic parameters (e.g., V_{max} , K_m).
- in vitro studies of drug-drug interactions using human biomaterials: for studies of other drugs inhibiting the new drug, the metabolite(s) inhibited, enzymatic pathways affected, range of inhibitor concentrations used, IC_{50} and K_i values and proposed mechanism of inhibition should be included. For studies of the new drug inhibiting other drugs, the drugs and metabolites inhibited should be included, along with the information mentioned above.
- population PK studies: co-variables studied, number and type of subjects or patients studied, summary statistical parameters and final estimates of mean ($\pm$ standard deviation) PK parameters.

2.7.3 Summary of clinical efficacy

A separate Section 2.7.3 should be provided for each indication, although closely related indications can be considered together. When more than one Section 2.7.3 is submitted, the sections should be labelled 2.7.3 pneumonia, 2.7.3 URI, etc.

2.7.3.1 Background and overview of clinical efficacy

This section should describe the program of controlled studies and other pertinent studies in the application that evaluated efficacy specific to the indication(s) sought. Any results of these studies that are pertinent to evaluation of safety should be discussed in Section 2.7.4, Summary of Clinical Safety.

The section should begin with a brief overview of the design of the controlled studies that were conducted to evaluate efficacy. These studies include dose-response, comparative efficacy, long-term efficacy, and efficacy studies in population subsets. Critical features of study design should be discussed, e.g., randomisation, blinding, choices of control treatment, choice of patient population, unusual design features such as crossover or randomised withdrawal designs, use of run-in periods, other methods of "enrichment", study endpoints, study duration, and prespecified plans for analysis of the study results. Although this section is intended to focus on clinical investigations, nonclinical data and clinical pharmacology data may also be referenced as appropriate to provide a comprehensive summary of human experience related to efficacy. This section should not include detailed information about individual studies.

2.7.3.2 Summary of results of individual studies

A tabular listing of all studies that provided (or were designed to provide) information relevant to product efficacy should generally be provided (see the section 2.7.3.6 Appendix), together with

narrative descriptions for important studies. The narrative descriptions should be brief, e.g., similar to an abstract for a journal article, and should describe critical design features and critical results. Similar studies may be described together, noting the individual study results and any important differences among the studies. For studies that also contributed significantly to the safety analysis, study narratives should include information about the extent of exposure of study subjects to the test drug or control agent, and how safety data were collected. These narratives can be abstracted from the synopses of the clinical study reports (ICH E3). References or electronic links to the full report of each study should be included in the narratives.

Narratives of any bridging studies using clinical endpoints, i.e., certain studies intended to evaluate the ability to extrapolate certain types of foreign clinical data to the new region (see ICH E5), should be included in this section. An analysis of the results of such studies, together with other information (e.g., PK and PD data) that addresses the ability to extrapolate the efficacy and safety results of foreign studies, should be performed if necessary. The conclusions of such an analysis should be noted at the start of Section 2.7.3.3.2, Comparison of Efficacy Results of All Studies, and the full report of the analysis should be provided in Module 5.

2.7.3.3 Comparison and analyses of results across studies

Using text, figures, and tables as appropriate (see the section 2.7.3.6 Appendix), the subsections of 2.7.3.3 should summarise all available data that characterise the efficacy of the drug. This summary should include analyses of all data, irrespective of their support for the overall conclusion and should, therefore, discuss the extent to which the results of the relevant studies do or do not reinforce each other. Any major inconsistencies in the data regarding efficacy should be addressed and any areas needing further exploration should be identified.

The section will generally utilise two kinds of analyses: comparison of results of individual studies, and analysis of data combined from various studies. Details of analyses that are too extensive to be reported in a summary document should be presented in a separate report, to be placed in Module 5, Section 5.3.5.3.

This section should also cross-reference important evidence from section 2.7.2, such as data that support the dosage and administration section of the labelling. These data include dosage and dose interval recommended, evidence pertinent to individualisation of dosage and need for modifications of dosage for specific subgroups (e.g., paediatric or geriatric subjects, or subjects with hepatic or renal impairment), and data relevant to dose-response or concentration response (PK/PD) relationships.

2.7.3.3.1 Study populations

The demographic and other baseline characteristics of patients across all efficacy studies should be described. The following should be included:

- the characteristics of the disease (e.g., severity, duration) and prior treatment in the study subjects, and study inclusion/exclusion criteria
- differences in baseline characteristics of the study populations in different studies or groups of studies.
- any differences between populations included in critical efficacy analyses and the overall patient population that would be expected to receive the drug when it is marketed should be noted.

- assessment of the number of patients who dropped out of the studies, time of withdrawal (a defined study day or visit during treatment or follow up period), and reasons for discontinuation.

Tabular presentations that combine and compare study populations across studies may be useful.

2.7.3.3.2 Comparison of efficacy results of all studies

The results of any bridging studies using clinical endpoints, i.e., certain studies used to evaluate the ability to extrapolate certain types of foreign clinical data to the new region (see ICH E5), should be summarised in this section. An analysis of the similarity of efficacy in subjects between regions, as well as any other information that may support extrapolation of the efficacy data to the new region, should be summarised here. An independent subsection can be created to summarize these kinds of data.

The results from all studies designed to evaluate the drug's efficacy should be summarised and compared, including studies with inconclusive or negative results. Important differences in study design such as endpoints, control group, study duration, statistical methods, patient population, and dose should be identified.

Comparisons of results across studies should focus on pre-specified primary endpoints. However, when the primary endpoints involved different variables or time points in different efficacy studies, it may be useful to provide cross-study comparisons of important data elements that were obtained in all studies. If results over time are important, results of studies may be displayed in a figure that illustrates the change over time in each study.

Confidence intervals for treatment effects should be given to aid in the interpretation of point estimates. If differences are shown between placebo and test drugs in the change from baseline, the baseline values and the magnitude of effect in all treatment groups, including placebo and active controls (if used), should generally be presented in the table or in text accompanying a figure. If the objective of an active control trial was to show equivalence or non-inferiority, the difference or the ratio of outcomes between treatments should be given with the confidence interval. The results should be evaluated by using the predefined criteria for defining equivalence or non-inferiority and the rationale for the criteria and support for the determination that the study (studies) had assay sensitivity should be provided (see ICH E10).

Important differences in outcomes between studies with a similar design should be delineated and discussed. Cross-study comparisons of factors that may have contributed to differences in outcomes should be described.

If a meta-analysis of the clinical studies is performed, it should be clear whether this analysis is conducted according to a predefined protocol or is a post hoc exercise. Any differences in trial designs or populations, or in efficacy measurements between trials should be described to allow assessment of the relevance and validity of the results and conclusions (See ICH E9). A detailed description of the methodology and results of the meta-analysis should generally be submitted in a separate report (section 5.3.5.3 of Module 5).

2.7.3.3.3 Comparison of results in sub-populations

The results of individual studies or overview analyses of efficacy in specific populations should be summarised in this section. The purpose of these comparisons should be to show whether the claimed treatment effects are observed consistently across all relevant sub-populations, especially those where there are special reasons for concern. The comparisons may highlight apparent variations in efficacy that require further investigation and discussion. The limitations of such analyses, however, should be

recognised (ICH E9), and it is important to note that their purpose is not to provide the basis for specific claims, nor to attempt to improve the evidence of efficacy in situations where the overall results are disappointing.

Given the limited sample sizes in individual studies, analyses across multiple studies should be performed to evaluate effects of major demographic factors (age, sex, and race) and of other predefined or relevant intrinsic and extrinsic factors (e.g., disease severity, prior treatment, concomitant illness, concomitant drugs, alcohol, tobacco, and body weight) on efficacy. Factors of special interest may arise from general concerns (e.g., the elderly) or from specific issues that are related to the pharmacology of the drug or that have arisen during earlier drug development. Efficacy in the paediatric population should be routinely analysed in applications for a proposed indication that occurs in children. Depending on the data set, if extensive, detailed efficacy analyses are performed, they can be placed in Module 5, with the results of those analyses reported here.

2.7.3.4 Analysis of clinical information relevant to dosing recommendations

This section should provide an integrated summary and analysis of all data that pertain to the dose-response or blood level-response relationships of effectiveness (including dose-blood level relationships), and thus have contributed to dose selection and choice of dose interval. Relevant data from nonclinical studies may be referenced, and relevant data from pharmacokinetic studies, other clinical pharmacology studies, and controlled and uncontrolled clinical studies should be summarised to illustrate these dose-response or blood level-response relationships. For pharmacokinetic and pharmacodynamic studies from which data have been summarised in Section 2.7.2.2, it may be appropriate to draw upon those data in this summary while cross-referencing the summaries in Section 2.7.2.2, without repeating those summaries.

While the interpretation of how these data support specific dosing recommendations should be supplied in the Clinical Overview document, the individual study results and any cross-study analyses that will be used to support the dosing recommendations (including the recommended starting and maximal doses, the method of dose titration, and any other instructions regarding individualisation of dosage) should be summarised here. Any identified deviations from relatively simple dose-response or blood-level response relationships due to non-linearity of pharmacokinetics, delayed effects, tolerance, enzyme induction, etc. should be described.

Any evidence of differences in dose-response relationships that result from a patient's age, sex, race, disease, or other factors should be described. Any evidence of different pharmacokinetic or pharmacodynamic responses should also be discussed, or discussions in Section 2.7.2 can be cross-referenced. The ways in which such differences were looked for, even if no differences were found, should be described (e.g., specific studies in subpopulations, analysis of efficacy results by subgroup, or blood level determinations of the test drug).

2.7.3.5 Persistence of efficacy and/or tolerance effects

Available information on persistence of efficacy over time should be summarised. The number of patients for whom long-term efficacy data are available, and the length of exposure, should be provided. Any evidence of tolerance (loss of therapeutic effects over time) should be noted. Examination of any apparent relationships between dose changes over time and long-term efficacy may be useful.

The primary focus should be on controlled studies specifically designed to collect long-term efficacy data, and such studies should be clearly differentiated from other, less rigorous, studies such as open

extension studies. This distinction also applies to specific studies designed for evaluation of tolerance and withdrawal effects. Data concerning withdrawal or rebound effects pertinent to product safety should be presented in the safety section (see section 2.7.4).

In long-term efficacy trials, the effect of premature discontinuation of therapy or switching to other therapies upon the assessment of the results should be considered. These issues might also be important for short term trials and should be addressed when discussing the results of these trials, if appropriate.

2.7.3.6 Appendix

Tables and figures should be embedded in the text of the appropriate sections when that enhances the readability of the document. Lengthy tables can be provided in the appendix at the end of the Section.

Tables should identify all studies pertinent to the evaluation of efficacy (including studies that were terminated or are not yet completed, studies that failed to show effectiveness for any reason, studies available only as publications, studies reported in full technical reports (ICH E3), and studies described in abbreviated reports); and should provide the most important results of those studies. Note, however, that unplanned interim analyses on ongoing studies are generally not needed or encouraged. When more than one section 2.7.3 is provided for an application with more than one indication, usually each section should have its own appendix with tables.

Illustrative tables for an antihypertensive drug are provided, but these examples will not be relevant to every application. In general, applications will require tables and/or figures that are developed specifically for the particular drug class and the studies that were carried out.

Table 2.7.3.1 Description of Clinical Efficacy and Safety Studies

Table 2.7.3.2 Results of Efficacy Studies

2.7.4 Summary of clinical safety

This section should be a summary of data relevant to safety in the intended patient population, integrating the results of individual clinical study reports as well as other relevant reports, e.g., the integrated analyses of safety that are routinely submitted in some regions.

The display of safety-related data can be considered at three levels (ICH E3):

- The extent of exposure (dose, duration, number of patients, type of patients) should be examined to determine the degree to which safety can be assessed from the database.
- The more common adverse events and changes in laboratory tests should be identified and classified, and their occurrence should be summarised.
- Serious adverse events (defined in ICH E2A) and other significant adverse events (defined in ICH E3) should be identified and their occurrence should be summarised. These events should be examined for frequency over time, particularly for drugs that may be used chronically.

The safety profile of the drug, described on the basis of analysis of all clinical safety data, should be outlined in a detailed, clear, and objective manner, with use of tables and figures.

2.7.4.1 Exposure to the drug

2.7.4.1.1 Overall safety evaluation plan and narratives of safety studies

The overall safety evaluation plan should be described briefly, including special considerations and observations concerning the nonclinical data, any relevant pharmacological class effects, and the sources of the safety data (controlled trials, open studies, etc). A tabular listing of all clinical studies that provided safety data, grouped appropriately, should generally be provided (see the section 2.7.4.7 Appendix). In addition to studies that evaluated efficacy and safety, and uncontrolled studies that generate safety information, this section includes studies that consider special safety issues. Examples would include studies to compare particular adverse event rates for two therapies, to assess safety in particular demographic subsets, to evaluate withdrawal or rebound phenomena, or to evaluate particular adverse events (e.g., sedation, sexual function, effects on driving, absence of a class adverse effect). Studies in indications for which approval is not being sought in the current application and ongoing studies would also be included here if they contribute to the safety analysis.

Narrative descriptions of these studies should be provided here, except that narrative descriptions for studies that contributed both efficacy and safety data should be included in Section 2.7.3.2 and cross-referenced here. The narratives should provide enough detail to allow the reviewer to understand the exposure of study subjects to the test drug or control agent, and how safety data were collected (including the methods used and the extent of safety monitoring of the subjects enrolled in the individual studies). If some studies are not analysed separately but are grouped for safety analysis, that should be noted, and a single narrative description can be provided.

2.7.4.1.2 Overall extent of exposure

A table (see example provided in the section 2.7.4.7 Appendix) and appropriate text should be generated to summarise the overall extent of drug exposure from all phases of the clinical study development programme. The table should indicate the numbers of subjects exposed in studies of different types and at various doses, routes, and durations. If a large number of different doses and/or durations of exposure were used, these can be grouped in a manner appropriate for the drug. Thus, for any dose or range of doses, duration of exposure can be summarised by the number of subjects exposed for specific periods of time, such as 1 day or less, 2 days to 1 week, 1 week to 1 month, 1 month to 6 months, 6 months to 1 year, more than 1 year (ICH E3). In some applications it may be important to identify diagnostic subgroups and/or groups receiving specific concomitant therapies deemed particularly relevant to safety assessment in the intended use.

The dose levels used for each subject in this presentation could be the maximum dose received by that subject, the dose with longest exposure, and/or the mean daily dose, as appropriate. In some cases, cumulative dose may be pertinent. Dosage may be given as the actual daily dose or on a mg/kg or mg/m² basis, as appropriate. If available, drug concentration data (e.g., concentration at the time of an adverse event, maximum plasma concentration, area under curve) may be helpful in individual subjects for correlation with adverse events or changes in laboratory variables.

It is assumed that all subjects who were enrolled and received at least one dose of the treatment are included in the safety analysis; if that is not so, an explanation should be provided.

2.7.4.1.3 Demographic and other characteristics of study population

A summary table should provide the reader with an overview of the demographic characteristics (Table 2.7.4.2) of the population that was exposed to the therapeutic agent during its development. Choice of

age ranges used should take into account considerations discussed in ICH E7 [Studies in Support of Special Populations: Geriatrics] and ICH E11 [Clinical Investigation of Medicinal Products in the Paediatric Population]. If the relative exposure of demographic groups in the controlled trials differed from overall exposure, it may be useful to provide separate tables.

In addition, one or more tables should show the relevant characteristics of the study population, and the numbers of subjects with special characteristics. Such characteristics could include:

- Severity of disease
- Hospitalisation
- Impaired renal function
- Concomitant illnesses
- Concomitant use of particular medications
- Geographical location

If these characteristics are distributed differently in controlled trials versus the overall database, it will generally be useful to present tables on both groupings.

The text accompanying the table(s) should mention any imbalance(s) between the drug and placebo and/or comparator regarding any of the above demographic characteristics, particularly if they could lead to differences in safety outcomes.

If certain subjects were excluded from studies (concomitant illness, severity of illness, concomitant medications), this fact should be noted.

Separate demographic tables should be provided for every indication, although closely related indications can be considered together, if study subject characteristics are such that risks are believed to be the same.

2.7.4.2 Adverse events

2.7.4.2.1 Analysis of adverse events

Data on the frequency of adverse events should be described in text and tables. Text should appear in the appropriate subsections of Section 2.7.4.2.1 and the tables that are not embedded in the text should be placed in the section 2.7.4.7 Appendix.

All adverse events occurring or worsening after treatment has begun ("treatment emergent signs and symptoms," those adverse events not seen at baseline and those that worsened even if present at baseline) should be summarised in tables listing each event, the number of subjects in whom the event occurred and the frequency of occurrence in subjects treated with the drug under investigation, with comparator drugs, and with placebo. Such tables could also present results for each dose and could be modified to show, e.g., adverse event rates by severity, by time from onset of therapy, or by assessment of causality.

When most of the relevant safety data are derived from a small number of studies (e.g., one or two studies), or when very different study subject populations were enrolled in the studies that were performed, presentation of data by study will often be appropriate. When the relevant exposure data is not concentrated in a small number of studies, however, grouping the studies and pooling the results to improve precision of estimates and sensitivity to differences should generally be considered.

910 While often useful, pooling of safety data across studies should be approached with caution because in
911 some cases interpretation can be difficult, and it can obscure real differences. In cases where
912 differences are apparent, it is more appropriate to present the data by study. The following issues
913 should be considered:

- 914 • it is most appropriate to combine data from studies that are of similar design, e.g., similar in dose,
915 duration, methods of determining adverse events, and population.
- 916 • if the incidence for a particular adverse event differs substantially across the individual studies in a
917 pool, the pooled estimate is less informative.
- 918 • any study with an unusual adverse event pattern should be presented separately.
- 919 • the appropriate extent of analysis depends on the seriousness of the adverse event and the
920 strength of evidence of drug causation. Differences in rates of drug-related, serious events or
921 events leading to discontinuation or dosage change deserve more investigation, whereas rates of
922 other adverse events do not merit elaborate analysis.
- 923 • examination of which subjects experience extreme laboratory value abnormalities ("outliers") may
924 be useful in identifying subgroups of individuals who are at particular risk for certain adverse
925 events.

926 Groups of studies that could be used in pooled safety analyses include:

- 927 • all controlled studies or subsets of controlled studies, such as all placebo-controlled studies, studies
928 with any positive control, studies with a particular positive control, or studies of particular
929 indications (and thus carried out in different populations). These groupings are considered the best
930 source of information about the more common adverse events and can distinguish drug-related
931 events from spontaneous events. Rates in control and treatment groups should be compared.
- 932 • all studies, excluding short-term studies in healthy subjects.
933 This grouping is most useful for evaluating rarer events.
- 934 • all studies using a particular dose route or regimen, or a particular concomitant therapy.
- 935 • studies in which adverse event reports are elicited by checklist or direct questioning, or studies in
936 which events are volunteered.
- 937 • pools of studies by region.

938 It is almost always useful to carry out the first two groupings; the others chosen would vary from drug
939 to drug and should be influenced by inspection of individual study results. Whatever methods are used,
940 it should be recognised that, as for results of single studies, any numerical rate is often only a rough
941 approximation of reality.

942 When a decision is made to pool data from several studies, the rationale for selecting the method used
943 for pooling should be described. It is common to combine the numerator events and the denominators
944 for the selected studies. Other methods for pooling results across studies are available, e.g., weighting
945 data from studies on the basis of study size or inversely to their variance.

946 If substantial differences are seen between clinical trials in the rates of adverse events, these
947 differences should be noted and possible reasons should be discussed (e.g., relevant differences in
948 study populations, in dose administration, or in methods of collecting adverse event data).

Adverse events should be described as shown in the individual study report (ICH E3). In combining data from many studies, it is important to use standardised terms to describe events and collect synonymous terms under a single preferred term. This can be done with a standard dictionary, and the MedDRA terminology (ICH M1 guideline) should be used. Until MedDRA can be fully implemented, other dictionaries can be used, but should be specified. Frequencies should be presented for preferred terms and for appropriately defined groupings. Examination of which adverse events led to change in therapy (discontinuation of drug use, change in dose, need for added therapy) can help in assessing the clinical importance of adverse events. These rates can be added to the adverse event rate tables, or can be presented in separate tables. Overall discontinuation rates by study may be useful but it is also important to specify the particular adverse events leading to discontinuation in a separate table. The preferred terms should be grouped by body system and arranged by decreasing frequency.

2.7.4.2.1.1 Common adverse events

Tabular displays of adverse event rates (see the section 2.7.4.7 Appendix) should be used to compare rates in treatment and control groups. For this analysis it may be helpful to combine the event severity categories and the causality categories, if they are used, leading to a simpler side-by-side comparison of treatment groups. It should be noted that while causality categories may be reported, if used, the presentation of the data should include total adverse events (whether deemed related or unrelated to treatment); evaluations of causality are inherently subjective and may exclude unexpected adverse events that are in fact treatment related. Additionally, comparisons of rates of adverse events between treatment and control groups in individual trials should be summarised here. It is often useful to tabulate rates in selected trials (see example table 2.7.4.4, in the Section 2.7.4.7 Appendix).

It is usually useful to examine more closely the more common adverse events that seem to be drug related (e.g., those that show that a dose response and/or a clear difference between drug and placebo rates) for relationship to relevant factors, including:

- dosage;
- mg/kg or mg/m² dose;
- dose regimen;
- duration of treatment;
- total dose;
- demographic characteristics such as age, sex, race;
- concomitant medication use;
- other baseline features such as renal status;
- efficacy outcomes;
- drug concentration, where available.

It may also be useful to summarise the results of examination of time of onset and duration for these drug-related events.

Rigorous statistical evaluations of the possible relationship of specific adverse events to each of the above factors are often unnecessary. It may be apparent from initial display and inspection of the data that there is no evidence of a significant relationship to demographic or other baseline features. In that case, no further analysis of these particular factors is needed. Further, it is not necessary that all such

analyses be presented in this report. When the safety analyses are too extensive to be presented in detail in this report, they may be presented in a separate report in Module 5, section 5.3.5.3, and summarised here.

Under certain circumstances, life table or similar analyses may be more informative than reporting of crude adverse event rates.

2.7.4.2.1.2 Deaths

A table in the Section 2.7.4.7 Appendix should list all deaths occurring while on study (including deaths that occurred shortly following treatment termination, e.g., within 30 days or as specified in the study protocol, as well as all other deaths that occurred later but may have resulted from a process that began during studies). Only deaths that are clearly disease-related per protocol definitions and not related to the investigational product, either in studies of conditions with high mortality such as advanced cancer or in studies where mortality from disease is a primary study endpoint, should be excepted from this listing (it is assumed, however, that these deaths would still be reported in the individual ICH E3 study reports). Even these deaths should be examined for any unexpected patterns between study arms, and further analysed if unexplained differences are observed. Deaths should be examined individually and analysed on the basis of rates in individual trials and appropriate pools of trials, considering both total mortality and cause-specific deaths. Potential relationships to the factors listed in Section 2.7.4.2.1.1 should also be considered. Although cause-specific mortality can be difficult to determine, some deaths are relatively easy to interpret. Thus deaths due to causes expected in the patient population (heart attacks and sudden death in an angina population) are individually not considered to be informative, but even one death due to a QT interval prolongation-associated arrhythmia, aplastic anaemia, or liver injury may be informative. Special caution is appropriate before an unusual death is attributed to concomitant illness.

2.7.4.2.1.3 Other serious adverse events

Summaries of all serious adverse events (other than death but including the serious adverse events temporally associated with or preceding the deaths) should be displayed. Serious adverse events that occurred after the drug use was discontinued should be included in this section. The display should include major laboratory abnormalities, abnormal vital signs, and abnormal physical observations that are considered serious adverse events using the ICH E2A definitions. Results of analyses or assessments of serious adverse events across studies should be presented. Serious events should be examined for frequency over time, particularly for drugs that may be used chronically. Potential relationships to the factors listed in Section 2.7.4.2.1.1 should also be considered.

2.7.4.2.1.4 Other significant adverse events

Marked haematologic and other laboratory abnormalities (other than those meeting the definition of serious) and any events that led to a substantial intervention (premature discontinuation of study drug, dose reduction, or substantial additional concomitant therapy), other than those reported as serious adverse events, should be displayed.

Events that led to premature discontinuation of study drug represent an important safety concern and deserve particular attention in the analysis of drug safety for two reasons. First, even for expected events (based on pharmacologic activity), the need to discontinue (or otherwise alter) treatment reflects the severity and perceived importance of the event to patient and physician. Second, discontinuation may represent a drug-related event not yet recognised as drug related. Adverse events

1031 leading to treatment discontinuation should be considered possibly drug-related even if this was not
1032 recognised initially and even if the event was thought to represent intercurrent illness. Reasons for
1033 premature treatment discontinuations should be discussed and rates of discontinuations should be
1034 compared across studies and compared with those for placebo and/or active control treatment. In
1035 addition, the study data should be examined for any potential relationships to the factors listed in
1036 Section 2.7.4.2.1.1.

1037 **2.7.4.2.1.5 Analysis of adverse events by organ system or syndrome**

1038 Assessment of the causality of, and risk factors for, deaths, other serious events, and other significant
1039 events is often complicated by the fact that they are uncommon. As a result, consideration of related
1040 events as a group, including less important events of potentially related pathophysiology, may be of
1041 critical value in understanding the safety profile. For example, the relationship to treatment of an
1042 isolated sudden death may become much clearer when considered in the context of cases of syncope,
1043 palpitations, and asymptomatic arrhythmias.

1044 It is thus generally useful to summarise adverse events by organ system so that they may be
1045 considered in the context of potentially related events including laboratory abnormalities. Such
1046 presentations of adverse events by organ system should be placed in subsections of section
1047 2.7.4.2.1.5, labelled as 2.7.4.2.1.5.1, 2.7.4.2.1.5.2, etc., and titled by the organ system under
1048 consideration. The list of organ systems to be addressed and the approach to grouping certain events
1049 should be selected as appropriate to best present the adverse event data for the medicinal product. If
1050 some adverse events tend to occur in syndromes (e.g., influenza-like syndrome, cytokine release
1051 syndrome), the sponsor may choose to create some subsections of 2.7.4.2.1.5 for syndromes rather
1052 than organ systems.

1053 The same data and summarisations should generally not be repeated in more than one subsection of
1054 Section 2.7.4.2.1. Instead, a summary presentation may be placed in one subsection and cross-
1055 referenced as needed in the other.

1056 **2.7.4.2.2 Narratives**

1057 The locations in the application of individual narratives of patient deaths, other serious adverse events,
1058 and other significant adverse events deemed to be of special interest because of clinical importance (as
1059 described in ICH E3 individual study reports) should be referenced here for the convenience of the
1060 reviewer. The narratives themselves should be a part of the individual study reports, if there is such a
1061 report. In cases where there is no individual study report (e.g., if many open studies are pooled as
1062 part of a safety analysis and are not individually described), narratives can be placed in Module 5,
1063 Section 5.3.5.3. Narratives should not be included here, unless an abbreviated narrative of particular
1064 events is considered critical to the summary assessment of the drug.

1065 **2.7.4.3 Clinical laboratory evaluations**

1066 This section should describe changes in patterns of laboratory tests with drug use. Marked laboratory
1067 abnormalities and those that led to a substantial intervention should be reported in section 2.7.4.2.1.3
1068 or 2.7.4.2.1.4. If these data are also presented in this section, this duplicate reporting should be made
1069 clear for the reviewer. The appropriate evaluations of laboratory values will in part be determined by
1070 the results seen, but, in general, the analyses described below should be provided. For each analysis,
1071 comparison of the treatment and control groups should be carried out, as appropriate and as

compatible with study sizes. In addition, normal laboratory ranges should be given for each analysis (ICH E3). Where possible, laboratory values should be provided in standard international units.

A brief overview of the major changes in laboratory values across the clinical studies should be provided. Laboratory data should include haematology, clinical chemistry, urinalysis and other data as appropriate. Each parameter at each time over the course of the study (e.g., at each visit) should be described at the following three levels:

- the central tendency, i.e., the group mean and median values,
- the range of values, and the number of subjects with abnormal values or with abnormal values of a certain size (e.g. twice the upper limit of normal, 5 times the upper limit; choices should be explained). When data are pooled from centres with differences in normal laboratory ranges, the methodology used in pooling should be described. The analysis of individual subject changes by treatment group can be shown with a variety of approaches (e.g., shift tables, see ICH E3 for examples).
- individual clinically important abnormalities, including those leading to discontinuations. The significance of the laboratory changes and the likely relation to the treatment should be assessed (e.g., by analysis of such features as relationship to dose, relation to drug concentration, disappearance on continued therapy, positive dechallenge, positive rechallenge, and the nature of concomitant therapy). Potential relationships to other factors listed in Section 2.7.4.2.1.1 should also be considered.

2.7.4.4 Vital signs, physical findings, and other observations related to safety

The manner of presenting cross-study observations and comparisons of vital signs (e.g., heart rate, blood pressure, temperature, respiratory rate), weight and other data (e.g., electrocardiograms, X-rays) related to safety should be similar to that for laboratory variables. If there is evidence of a drug effect, any dose-response or drug concentration-response relationship or relationship to individual variables (e.g., disease, demographics, concomitant therapy) should be identified and the clinical relevance of the observation described. Particular attention should be given to changes not evaluated as efficacy variables and to those considered to be adverse events. Particular attention should be given to studies that were designed to evaluate specific safety issues, e.g., studies of QT interval prolongation.

2.7.4.5 Safety in special groups and situations

2.7.4.5.1 Intrinsic factors

This section should summarise safety data pertinent to individualising therapy or patient management on the basis of demographic and other factors defined as "intrinsic ethnic factors" in ICH E5. These factors include age, sex, height, weight, lean body mass, genetic polymorphism, body composition, other illness and organ dysfunction. Safety in the paediatric population should be routinely analysed in applications for a proposed indication that occurs in children. Analysis of the impact of such factors on safety outcomes should have been presented in other sections but should be summarised here, together with pertinent PK or other information, e.g., in patients with renal or hepatic disease. If a sufficiently large number of subjects with a given co-morbid condition such as hypertension, heart disease, or diabetes, was enrolled, analyses should be carried out to assess whether the co-morbid condition affected the safety of the drug under study. Cross reference should be made to the tables or description of adverse events when analyses of such sub-groups has been carried out.

1114 **2.7.4.5.2 Extrinsic factors**

1115 This section should summarise safety data pertinent to individualising therapy or patient management
1116 on the basis of factors defined as "extrinsic ethnic factors" in ICH E5. These are factors associated with
1117 the patient environment. Examples are the medical environment, use of other drugs (see 2.7.4.5.3,
1118 Drug Interactions), use of tobacco, use of alcohol, and food habits.

1119 For example, if a potential interaction with alcohol is suggested by the metabolic profile, by the results
1120 of studies, by post-marketing experience, or by information on similar drugs, information should be
1121 provided here.

1122 **2.7.4.5.3 Drug interactions**

1123 Studies on potential drug-drug or drug-food interactions should be summarised in the Summary of
1124 Clinical Pharmacology Studies section of the CTD (Section 2.7.2). The potential impact on safety of
1125 such interactions should be summarised here, based on PK, PD, or clinical observations. Any observed
1126 changes in the adverse event profile, changes in blood levels thought to be associated with risk, or
1127 changes in drug effects associated with other therapy should be presented here.

1128 **2.7.4.5.4 Use in pregnancy and lactation**

1129 Any information on safety of use during pregnancy or breast-feeding that becomes available during
1130 clinical development or from other sources should be summarised here.

1131 **2.7.4.5.5 Overdose**

1132 All available clinical information relevant to overdose, including signs/symptoms, laboratory findings,
1133 and therapeutic measures/treatments and antidotes (if available) should be summarised and
1134 discussed. Information on the efficacy of specific antidotes and dialysis should be provided if available.

1135 **2.7.4.5.6 Drug abuse**

1136 Any relevant studies/information regarding the investigation of the dependence potential of a new
1137 therapeutic agent in animals and in humans should be summarised and cross-referenced to the
1138 nonclinical summary. Particularly susceptible patient populations should be identified.

1139 **2.7.4.5.7 Withdrawal and rebound**

1140 Any information or study results pertinent to rebound effects should be summarised. Events that occur,
1141 or increase in severity, after discontinuation of double-blind or active study medication should be
1142 examined to see if they are the result of withdrawal of the study medication. Particular emphasis
1143 should be given to studies designed to evaluate withdrawal and/or rebound.

1144 Data concerning tolerance should be summarised under section 2.7.3.5 in the Summary of Clinical
1145 Efficacy.

1146 **2.7.4.5.8 Effects on ability to drive or operate machinery or impairment of mental ability**

1147 Safety data related to any impairment in the senses, co-ordination, or other factor that would result in
1148 diminished ability to drive a vehicle or operate machinery or that would impair mental ability should be
1149 summarised. This includes relevant adverse effects reported in safety monitoring (e.g., drowsiness)

1150 and specific studies concerning effects on ability to drive or operate machinery or impairment of
1151 mental ability.

1152 **2.7.4.6 Post-marketing data**

1153 If the drug has already been marketed, all relevant post-marketing data available to the applicant
1154 (published and unpublished, including periodic safety update reports if available) should be
1155 summarised. The periodic safety update reports can be included in Module 5. Details of the number of
1156 subjects estimated to have been exposed should be provided and categorised, as appropriate, by
1157 indication, dosage, route, treatment duration, and geographic location. The methodology used to
1158 estimate the number of subjects exposed should be described. If estimates of the demographic details
1159 are available from any source, these should be provided.

1160 A tabulation of serious events reported after the drug is marketed should be provided, including any
1161 potentially serious drug interactions.

1162 Any post-marketing findings in subgroups should be described.

1163 **2.7.4.7 Appendix**

1164 Tabular presentations should be provided that summarise the important results from all studies
1165 pertinent to the evaluation of safety and particularly to support product labelling.

1166 Tables and figures should be embedded in the text of the appropriate sections when that enhances the
1167 readability of the document. Lengthy tables can be provided in the appendix at the end of the Section.

1168 A few illustrative tables are provided, but a clinical summary will routinely need tables and figures that
1169 have been developed for the particular drug, drug class, and clinical indication(s).

1170 See sections 2.7.4.2.1, 2.7.4.2.2.3, and 2.7.4.3 of this guidance for additional discussion regarding the
1171 content of section 2.7.4 tables.

1172 Table 2.7.4.1 Study Subject Drug Exposure by Mean Daily Dose and Duration of Exposure

1173 Table 2.7.4.2 Demographic Profile of Patients in Controlled Trials

1174 Table 2.7.4.3 Incidence of Adverse Events in Pooled Placebo and Active Controlled Trials

1175 Table 2.7.4.4 Incidence of Adverse Events in the Largest Trials

1176 Table 2.7.4.5 Patient Withdrawals by Study: Controlled Trials

1177 Table 2.7.4.6 Listing of Deaths

1178 **2.7.5 Literature references**

1179 A list of references cited in the Clinical Summary should be provided. Copies of all important
1180 references should be provided in Module 5, Section 5.4. The reference list should indicate which
1181 references are available in Module 5, Section 5.4. All references that have not been provided should be
1182 available upon request.

1183 **2.7.6 Synopses of individual studies**

1184 The ICH E3 guideline (Structure and Content of Clinical Study Reports) suggests inclusion of a study
1185 synopsis with each clinical study report, and provides one example of a format for such synopses.

1186 This section should include the table entitled Listing of Clinical Studies, described in guidance for
1187 Module 5, followed by all individual study synopses organised in the same sequence as the study
1188 reports in Module 5.

1189 It is expected that one synopsis will be prepared per study for use in all regions, and that the same
1190 synopsis will be included in this section and as part of the clinical study report in Module 5. The length
1191 of a synopsis will usually be up to 3 pages, but a synopsis for a more complex and important study
1192 may be longer, e.g. 10 pages. Within the individual synopsis, tables and figures should be used as
1193 appropriate to aid clarity.

1194 Table 2.7.1.1

1195 Summary of bioavailability studies

Study Ref. No.	Study Objective	Study Design	Treatments (Dose, Dosage Form, Route) [Product ID]	Subjects (No.(M/F) type Age: mean (range)	Mean Parameters (+/- SD)						Study Report Location
					Cmax (mg/L)	Tmax (hr)	AUC* (mg/L x hr)	Cmin** (mg/L)	T1/2 (hr)	Other	
192 (Japan)	Pilot relative BA study comparing the absorption from a 200mg tablet batch to a 200mg reference batch.	Open, randomized, cross-over, single 200 mg dose	200mg Tab., p.o. [17762]	20 (10/10) Healthy volunteer 27 y (20-35)	83 ± 21	1	217 ± 20		1		
			200mg Tab.. p.o. [19426]		80 ± 32	0.5	223 ± 19		2.9		
195 (Japan)	Comparative BA study of xx under fasted and fed conditions	Open, randomized, cross-over, single dose	200mg Tab, p.o. [19426]	30 (15/15) Healthy volunteer 32 y (26-50)	83 ± 21 120 ± 30	1 2	217 ± 20 350 ± 40				

1196 AUC*: AUC_{TAU} or AUC_{inf}

1197 Cmin **: For multiple dose studies

1198 **Table 2.7.1.2**

1199 **Summary of *In vitro* Dissolution Studies**

Study Ref. No.	Product ID/Batch No.	Dosage Form	Conditions	No. of Dosage Units	Collection times Mean % Dissolved (range)	Study Report Location
1821	979-03	25mg Cap.	Dissolution: Apparatus 2 (USP) Speed of Rotation: 50 rpm Medium/Temperature: Water 37°	12	10 20 30 (min) 42 (32-49) 71 (58-85) 99 (96-100) (%)	

1200 Table 2.7.2.1

1201 Summary of drug-drug interaction PK studies

Study/ Protocol # (Country)	Product ID/Batch # (NME)	Study Objective	Study Design	# Subject s Entered /Comple ted (M/F)	HV/P ¹ (Age: Mean, range)	Treatments		Mean Pharmacokinetic Parameters (%CV) Substrate Drug					Mean ratio ² Confidence interval		Locatio n
						Substrat e	Interacti ng Drug	Cmax	Tmax	AUC	T1/2	CL/kg	Cmax	AUC	
001 (USA)	19B Batch 0034	Effect of warfarin on Drug X	Rando mized, Cross over	(8M/4F) / (7M/4F)	HV (34, 20- 41)	Drug X 100 mg bid x 7d	Placebo	45 (18) Φg/mL	2.0 (30) hr	456 (24) Φg*hr / mL	4.25 (30) hr	0.05 (20) mL/mi n/kg	1.16 1.01- 1.30	1.16 1.03- 1.34	
						Drug X 100 mg bid x 7d	Warfarin 10 mg qd x 7d	52 (20) Φg/mL	2.1 (35) hr	530 (27) Φg*hr / mL	4.75 (35) hr	0.04 (22) mL/mi n/kg			
001 (USA)	19B Batch 0034	Effect of drug X on warfarin	Rando mized, Cross over	(8M/4F) / (7M/4F)	HV (34, 20- 41)	Warfari n 10 mg qd x 7d	Placebo	12 (25) Φg/mL	1.5 (30) hr	60 (37) Φg*hr / mL	40 (35) hr	0.04 (30) mL/mi n/kg	1.08 0.92- 1.24	1.07 0.92- 1.18	

						Warfari n 10 mg qd x 7d	drug X 100 mg bid x 7d	13 (20) Φg/mL	1.45 (27) hr	64 (39) Φg*hr / mL	42 (37) hr	0.39 (34) mL/mi n/kg			
002 (UK)	19B2 Batch 0035	Effect of Cimetidin e on Drug X	Cross over, Single sequen ce	(4M/8F) (4M/8F)	HV (30, 19- 45)	Drug X 50 mg bid x 5d	Placebo	49 (18) Φ/mL	2.1 (30) hr	470 (24) Φg*hr / mL	4.4 (30) hr	0.05 (20) mL/mi n/kg	1.22 1.03- 1.40	1.36 1.11- 1.53	
						Drug X 50 mg bid x 5d	Cimetidin e 200 mg bid x 5d	60 (10) Φg/mL	2.2 (30) hr	640 (24) Φg*hr / mL	5.2 (30) hr	0.03 (20) mL/mi n/kg			

1202 ¹HV=Healthy Volunteers, P=Patients

1203 ²Value for substrate with interacting drug / value with placebo

1204

Table 2.7.3.1

Description of clinical efficacy and safety studies

Study ID	Number of Study Centers Location(s)	Study start Enrollment status, date Total enrollment / Enrollment goal	Design Control type	Study & Ctrl Drugs Dose,Route & Regimen	Study Objective	# subjs by arm entered/ compl.	Duration	Gender M/F Median Age (Range)	Diagnosis Inclusion Criteria	Primary Endpoint(s)
PG-2476	1 U. Antarctica	Aug-94 Completed Apr 98 50 / 50	Randomised, double blind, parallel Placebo	TP: 30 mg po bid Pbo	Efficacy and Safety	27/24 23/21	4 weeks	27/23 38 (20-64)	Mild hypertension Diastolic 90-100 Systolic 150-170	Change from baseline systolic and diastolic pressure at 4 weeks.
PG-2666	4 Affiliated Physicians of Florida,	May-98 Ongoing as of May 2001 126/	Randomised, open label, parallel Placebo and Dose-response	TP: 100 mg po bid TP: 50 mg po bid	Efficacy and Safety, Long-term efficacy and	34/30 30/28	4 weeks, followed by 12 weeks open-label	66/60 55 (24-68)	Mild hypertension Systolic 150-170 Diastolic 90-100	Change from baseline systolic and diastolic pressure at 4 weeks and at 12 weeks.

	Smith & Jones CRO	400		TP: 25 mg po bid	safety	34/32				
				Placebo		28/26				

1205

Table 2.7.3.2

Results of efficacy studies

Study	Treatment Arm	# Enrolled/Completed	Mean systolic and diastolic BP			Primary Endpoint Placebo-subtracted change in DBP at 40 weeks	Statistical test / P value	Secondary Endpoints % normalised* * (ITT analysis)	Other Comments
			Baseline	20 wks	40 wks				
PG-2678	TP: 100 mg po bid	34/30	162/96	140/85	138/84	6		88	
	TP: 50 mg po bid	30/28	165/97	146/87	146/87	4		78	
	TP: 25 mg po bid	34/32	167/96	148/88	148/88	2		50	
	TP: 10 mg po bid	26/20	162/95	153/93	153/93	-4		20	
	Placebo	28/26	166/97	160/92	159/91			30	

1206

**Provide definition

1207

Table 2.7.4.1 Study subject drug exposure by mean daily dose and duration of exposure Intravenous formulation N= Cutoff Date:								
Duration (Weeks)	Mean Daily Dose (mg)							
	0 < Dose ≤ 5mg	5 < Dose ≤ 10mg	10 < Dose ≤ 20mg	20 < Dose ≤ 30mg	30 < Dose ≤ 50mg	50mg < Dose	Total (Any Dose)	Percent
0 < Dur ≤ 1								
1 < Dur ≤ 2								
2 < Dur ≤ 4								
4 < Dur ≤ 12								
12 < Dur ≤ 24								
24 < Dur ≤ 48								
48 < Dur ≤ 96								
Dur >96								
Total (Any Duration)								
Percent								

1208 Similar tables can be generated for median, for modal, and for maximum dose, or for dose of longest exposure. The same table can be generated for any
 1209 pool of studies and any subgroup of interest, e.g., on the basis of age groupings, sex, ethnic factors, comorbid conditions, concomitant medications, or any
 1210 combination of these factors.

1211 Dose can also be expressed as mg/kg, mg/m2, or in terms of plasma concentration if such data are available.

Table 2.7.4.2 Demographic profile of patients in controlled trials cutoff date:			
	Treatment Groups		
	Test Product N =	Placebo N =	Active Control N =
Age (years) Mean $\pm$ SD Range Groups <18 18 - 40 40 - 64 65 - 75 >75	50 $\pm$ 15 20-85 N (%) N (%) N (%) N (%) N (%)	 N (%) N (%) N (%) N (%) N (%)	 N (%) N (%) N (%) N (%) N (%)
Sex Female Male	N (%) N (%)	N (%) N (%)	N (%) N (%)
Race Asian Black Caucasian Other	N (%) N (%) N (%) N (%)	N (%) N (%) N (%) N (%)	N (%) N (%) N (%) N (%)
Other Factors			

1212

1213

Table 2.7.4.3 Incidence of adverse events in pooled placebo and active controlled trial database							
Body System / Adverse Event	Test Drug			Placebo	Active Control 1	Active Control 2	
	All doses n = 1685	10 mg n = 968	20 mg n = 717	n = 425	20 mg n = 653	50 mg n = 334	100 mg n = 546
Body as a whole							
Dizziness	19 (1%)	7 (1%)	12 (2%)	6 (1%)	23 (4%)	1 (<1%)	3 (1%)
Etc.							
Cardiovascular							
Postural Hypotension	15 (1%)	10 (1%)	5 (1%)	2 (<1%)	7 (1%)	6 (2%)	12 (2%)
Etc.							
Gastrointestinal							
Constipation							

1214

1215

Table 2.7.4.4

Incidence of adverse events in individual studies

	Reported incidence by Treatment Groups							
Body System / Adverse Event	Study 95-0403			Study 96-0011		Study 97-0007		Study 98-0102s
	Drug x 60 mg bid N =104	Drug x 30 mg bid N =102	Placebo N = 100	Drug x 60 mg bid N = 500	Placebo N=495	Drug x 60 mg bid N=200	Drug y 100 mg qd N=200	Drug x 60 mg bid N=800
Body as a whole								
Dizziness	N (%)	N (%)	N (%)	N (%)	N (%)	N (%)	N (%)	N (%)
Etc.	N (%)	N (%)	N (%)	N (%)	N (%)	N (%)	N (%)	N (%)
Cardiovascular								
Postural Hypotension								
Etc.								
Gastrointestinal								
Constipation								

1216

Table 2.7.4.5

Patient withdrawals⁵ by study: controlled trials

Cutoff Date:

Studies		Total Withdrawal				Reason for Withdrawal			Number without post-withdrawal efficacy data
		Total	Male/ Female	Age > 65	Race (identify groupings) / / /	Adverse Events N (%)	Lack of Efficacy N (%)	Other N (%)	N (%)
Study	Drug X	N (%)	N (%) / N (%)	N (%)	N (%) / N (%) / N (%)				
XXX	Placebo								
Study	Drug X								
AAA	Comparator A								
Study	Drug X								
BBB	Comparator B								
Study	Drug X								
CCC	Comparator C								
All Trials									

⁵ Withdrawals are all subjects who were enrolled but did not complete the planned course of treatment (includes subjects who discontinued treatment or changed to a different treatment prematurely and/or were lost to follow-up)

1217 Note: withdrawal data can be subdivided by dose level, if that appears to be useful.

1218

Table 2.7.4.6 Listing of deaths Treatment: Test Product Cutoff Date:											
Trial / Source ¹	Center	Patient ID	Age (yrs)	Sex	Dose (mg)	Duration of exposure (Days)	Diagnosis	Cause of Death	Other medications	Other medical conditions	Location of narrative description

1219 1PM = deaths from postmarketing experience

1220 This listing should include all deaths meeting the inclusion rule, whether arising from a clinical trial or from any secondary source, e.g., postmarketing
1221 experience. In electronic applications, a link to the narrative or other documentation regarding the event should be provided.

1222 A footnote should describe the rule for including deaths in the table, e.g., all deaths that occurred during a period of drug exposure or within a period of up
1223 to 30 days following discontinuation from drug and also those occurring later but resulting from adverse events that had an onset during exposure or during
1224 the 30 day follow up period. Other rules may be equally appropriate.

1225 Similar lists should be provided for patients exposed to placebo and active control drugs.

1226 **Module 5: clinical study reports**

1227 **Preamble**

1228 Through the ICH process, a guideline has been published on the structure and content of clinical study
1229 reports (E3). This document provides guidance on the organisation of these study reports, other
1230 clinical data, and references within a Common Technical Document (CTD) for registration of a
1231 pharmaceutical product for human use. These elements should facilitate the preparation and review of
1232 a marketing application.

1233 This guideline is not intended to indicate what studies are required for successful registration. It
1234 indicates an appropriate organization for the clinical study reports that are in the application.

1235 **Detailed organisation of clinical study reports and related information in** 1236 **module 5**

1237 This guideline recommends a specific organization for the placement of clinical study reports and
1238 related information to simplify preparation and review of dossiers and to ensure completeness. The
1239 placement of a report should be determined by the primary objective of the study. Each study report
1240 should appear in only one section. Where there are multiple objectives, the study should be cross-
1241 referenced in the various sections. An explanation such as "not applicable" or "no study conducted"
1242 should be provided when no report or information is available for a section or subsection.

1243 **5.1 Table of contents of module 5**

1244 **A Table of Contents for study reports should be provided.**

1245 **5.1 Table of Contents of Module 5**

1246 **5.2 Tabular Listing of All Clinical Studies**

1247 **5.3 Clinical Study Reports**

1248 **5.3.1 Reports of Biopharmaceutic Studies**

1249 5.3.1.1 Bioavailability (BA) Study Reports

1250 5.3.1.2 Comparative BA and Bioequivalence (BE) Study Reports

1251 5.3.1.3 *In vitro-In vivo* Correlation Study Reports

1252 5.3.1.4 Reports of Bioanalytical and Analytical Methods for Human Studies

1253 **5.3.2 Reports of Studies Pertinent to Pharmacokinetics using Human Biomaterials**

1254 5.3.2.1 Plasma Protein Binding Study Reports

1255 5.3.2.2 Reports of Hepatic Metabolism and Drug Interaction Studies

1256 5.3.2.3 Reports of Studies Using Other Human Biomaterials

1257 **5.3.3 Reports of Human Pharmacokinetic (PK) Studies**

1258 5.3.3.1 Healthy Subject PK and Initial Tolerability Study Reports

1259 5.3.3.2 Patient PK and Initial Tolerability Study Reports

1260	5.3.3.3 Intrinsic Factor PK Study Reports
1261	5.3.3.4 Extrinsic Factor PK Study Reports
1262	5.3.3.5 Population PK Study Reports
1263	5.3.4 Reports of Human Pharmacodynamic (PD) Studies
1264	5.3.4.1 Healthy Subject PD and PK/PD Study Reports
1265	5.3.4.2 Patient PD and PK/PD Study Reports
1266	5.3.5 Reports of Efficacy and Safety Studies
1267	5.3.5.1 Study Reports of Controlled Clinical Studies Pertinent to the Claimed Indication
1268	5.3.5.2 Study Reports of Uncontrolled Clinical Studies
1269	5.3.5.3 Reports of Analyses of Data from More Than One Study
1270	5.3.5.4 Other Clinical Study Reports
1271	5.3.6 Reports of Post-Marketing Experience
1272	5.3.7 Case Report Forms and Individual Patient Listings
1273	5.4 Literature References
1274	5.2 Tabular listing of all clinical studies
1275	A tabular listing of all clinical studies and related information should be provided. For each study, this
1276	tabular listing should generally include the type of information identified in Table 5.1 of this guideline.
1277	Other information can be included in this table if the applicant considers it useful. The sequence in
1278	which the studies are listed should follow the sequence described in Section 5.3 below. Use of a
1279	different sequence should be noted and explained in an introduction to the tabular listing
1280	5.3 Clinical study reports
1281	5.3.1 Reports of biopharmaceutic studies
1282	BA studies evaluate the rate and extent of release of the active substance from the medicinal product.
1283	Comparative BA or BE studies may use PK, PD, clinical, or <i>in vitro</i> dissolution endpoints, and may be
1284	either single dose or multiple dose. When the primary purpose of a study is to assess the PK of a
1285	drug, but also includes BA information, the study report should be submitted in Section 5.3.1, and
1286	referenced in Sections 5.3.1.1 and/or 5.3.1.2.
1287	5.3.1.1 Bioavailability (BA) study reports
1288	BA studies in this section should include
1289	• studies comparing the release and systemic availability of a drug substance from a solid oral
1290	dosage form to the systemic availability of the drug substance given intravenously or as an oral
1291	liquid dosage form
1292	• dosage form proportionality studies, and
1293	• food-effect studies.

1294 **5.3.1.2 Comparative BA and bioequivalence (BE) study reports**

1295 Studies in this section compare the rate and extent of release of the drug substance from similar drug
1296 products (e.g., tablet to tablet, tablet to capsule). Comparative BA or BE studies may include
1297 comparisons between

- 1298 • the drug product used in clinical studies supporting effectiveness and the to-be-marketed drug
1299 product,
- 1300 • the drug product used in clinical studies supporting effectiveness and the drug product used in
1301 stability batches, and
- 1302 • similar drug products from different manufacturers.

1303 **5.3.1.3 In vitro – in vivo correlation study reports**

1304 *In vitro* dissolution studies that provide BA information, including studies used in seeking to correlate
1305 *in vitro* data with *in vivo* correlations, should be placed in Section 5.3.1.3. Reports of *in vitro*
1306 dissolution tests used for batch quality control and/or batch release should be placed in the Quality
1307 section of the CTD.

1308 **5.3.1.4 Reports of bioanalytical and analytical methods for human studies**

1309 Bioanalytical and/or analytical methods for biopharmaceutical studies or *in vitro* dissolution studies
1310 should ordinarily be provided in individual study reports. Where a method is used in multiple studies,
1311 the method and its validation should be included once in Section 5.3.1.4 and referenced in the
1312 appropriate individual study reports.

1313 **5.3.2 Reports of studies pertinent to pharmacokinetics using human**
1314 **biomaterials**

1315 Human biomaterials is a term used to refer to proteins, cells, tissues and related materials derived
1316 from human sources that are used *in vitro* or ex vivo to assess PK properties of drug substances.
1317 Examples include cultured human colonic cells that are used to assess permeability through biological
1318 membranes and transport processes, and human albumin that is used to assess plasma protein
1319 binding. Of particular importance is the use of human biomaterials such as hepatocytes and/or hepatic
1320 microsomes to study metabolic pathways and to assess drug-drug interactions with these pathways.
1321 Studies using biomaterials to address other properties (e.g., sterility or pharmacodynamics) should not
1322 be placed in the Clinical Study Reports Section, but in the Nonclinical Study Section (Module 4).

1323 **5.3.2.1 Plasma protein binding study reports**

1324 Ex vivo protein binding study reports should be provided here. Protein binding data from PK blood
1325 and/or plasma studies should be provided in Section 5.3.3.

1326 **5.3.2.2 Reports of hepatic metabolism and drug interaction studies**

1327 Reports of hepatic metabolism and metabolic drug interaction studies with hepatic tissue should be
1328 placed here.

1329 **5.3.2.3 Reports of studies using other human biomaterials**

1330 Reports of studies with other biomaterials should be placed in this section.

1331 **5.3.3 Reports of human pharmacokinetic (PK) studies**

1332 Assessment of the PK of a drug in healthy subjects and/or patients is considered critical to designing
1333 dosing strategies and titration steps, to anticipating the effects of concomitant drug use, and to
1334 interpreting observed pharmacodynamic differences. These assessments should provide a description
1335 of the body's handling of a drug over time, focusing on maximum plasma concentrations (peak
1336 exposure), area-under-curve (total exposure), clearance, and accumulation of the parent drug and its
1337 metabolite(s), in particular those that have pharmacological activity.

1338 The PK studies whose reports should be included in Sections 5.3.3.1 and 5.3.3.2 are generally
1339 designed to (1) measure plasma drug and metabolite concentrations over time, (2) measure drug and
1340 metabolite concentrations in urine or faeces when useful or necessary, and/or (3) measure drug and
1341 metabolite binding to protein or red blood cells.

1342 On occasion, PK studies may include measurement of drug distribution into other body tissues, body
1343 organs, or fluids (e.g., synovial fluid or cerebrospinal fluid), and the results of these tissue distribution
1344 studies should be included in Section 5.3.3.1 to 5.3.3.2, as appropriate. These studies should
1345 characterise the drug's PK and provide information about the absorption, distribution, metabolism, and
1346 excretion of a drug and any active metabolites in healthy subjects and/or patients. Studies of mass
1347 balance and changes in PK related to dose (e.g., determination of dose proportionality) or time (e.g.,
1348 due to enzyme induction or formation of antibodies) are of particular interest and should be included in
1349 Sections 5.3.3.1 and/or 5.3.3.2. Apart from describing mean PK in normal and patient volunteers, PK
1350 studies should also describe the range of individual variability. In the ICH E5 guideline on Ethnic
1351 Factors in the Acceptance of Foreign Data, factors that may result in different responses to a drug in
1352 different populations are categorised as intrinsic ethnic factors or extrinsic ethnic factors. In this
1353 document, these categories are referred to as intrinsic factors and extrinsic factors, respectively.
1354 Additional studies can also assess differences in systemic exposure as a result of changes in PK due to
1355 intrinsic (e.g., age, gender, racial, weight, height, disease, genetic polymorphism, and organ
1356 dysfunction) and extrinsic (e.g., drug-drug interactions, diet, smoking, and alcohol use) factors.
1357 Reports of PK studies examining the influence of intrinsic and extrinsic factors on exposure should be
1358 organised in Sections 5.3.3.3 and 5.3.3.4, respectively.

1359 In addition to standard multiple-sample PK studies, population PK analyses based on sparse sampling
1360 during clinical studies can also address questions about the contributions of intrinsic and extrinsic
1361 factors to the variability in the dose-PK-response relationship. Because the methods used in population
1362 PK studies are substantially different from those used in standard PK studies, these studies should be
1363 placed in Section 5.3.3.5.

1364 **5.3.3.1 Healthy subject PK and initial tolerability study reports**

1365 Reports of PK and initial tolerability studies in healthy subjects should be placed in this section.

1366 **5.3.3.2 Patient PK and initial tolerability study reports**

1367 Reports of PK and initial tolerability studies in patients should be placed in this section.

1368 **5.3.3.3 Intrinsic factor PK study reports**

1369 Reports of PK studies to assess effects of intrinsic factors, should be placed in this section.

1370 **5.3.3.4 Extrinsic factor PK study reports**

1371 Reports of PK studies to assess effects of extrinsic factors, should be placed in this section.

1372 **5.3.3.5 Population PK study reports**

1373 Reports of population PK studies based on sparse samples obtained in clinical trials including efficacy
1374 and safety trials, should be placed in this section.

1375 **5.3.4 Reports of human pharmacodynamic (PD) studies**

1376 Reports of studies with a primary objective of determining the PD effects of a drug product in humans
1377 should be placed in this section. Reports of studies whose primary objective is to establish efficacy or
1378 to accumulate safety data, however, should be placed in Section 5.3.5.

1379 This section should include reports of 1) studies of pharmacologic properties known or thought to be
1380 related to the desired clinical effects (biomarkers), 2) short-term studies of the main clinical effect, and
1381 3) PD studies of other properties not related to the desired clinical effect. Because a quantitative
1382 relationship of these pharmacological effects to dose and/or plasma drug and metabolite
1383 concentrations is usually of interest, PD information is frequently collected in dose response studies or
1384 together with drug concentration information in PK studies (concentration-response or PK/PD studies).
1385 Relationships between PK and PD effects that are not obtained in well-controlled studies are often
1386 evaluated using an appropriate model and used as a basis for designing further dose-response studies
1387 or, in some cases, for interpreting effects of concentration differences in population subsets.

1388 Dose-finding, PD and/or PK-PD studies can be conducted in healthy subjects and/or patients, and can
1389 also be incorporated into the studies that evaluate safety and efficacy in a clinical indication. Reports
1390 of dose-finding, PD and/or PK/PD studies conducted in healthy subjects should be placed in Section
1391 5.3.4.1, and the reports for those studies conducted in patients should be placed in Section 5.3.4.2.

1392 In some cases, the short-term PD, dose-finding, and/or PK-PD information found in pharmacodynamic
1393 studies conducted in patients will provide data that contribute to assessment of efficacy, either
1394 because they show an effect on an acceptable surrogate marker (e.g., blood pressure) or on a clinical
1395 benefit endpoint (e.g., pain relief). Similarly, a PD study may contain important clinical safety
1396 information. When these studies are part of the efficacy or safety demonstration, they are considered
1397 clinical efficacy and safety studies that should be included in Section 5.3.5, not in Section 5.3.4.

1398 **5.3.4.1 Healthy subject PD and PK/PD study reports**

1399 PD and/or PK/PD studies having non-therapeutic objectives in healthy subjects should be placed in this
1400 section

1401 **5.3.4.2 Patient PD and PK/PD study reports**

1402 PD and/or PK/PD studies in patients should be submitted in this section.

5.3.5 Reports of efficacy and safety studies

This section should include reports of all clinical studies of efficacy and/or safety carried out with the drug, conducted by the sponsor, or otherwise available, including all completed and all ongoing studies of the drug in proposed and non-proposed indications. The study reports should provide the level of detail appropriate to the study and its role in the application. ICH E3 describes the contents of a full report for a study contributing evidence pertinent to both safety and efficacy. Abbreviated reports can be provided for some studies (see ICH E3 and individual guidance by region).

Within Section 5.3.5, studies should be organised by design (controlled, uncontrolled) and, within controlled studies, by type of control. Within each section, studies should be categorized further, ordered by whether the study report is complete or abbreviated (ICH E3), with completely reported studies presented first. Published reports with limited or no further data available to the sponsor should be placed last in this section.

In cases where the application includes multiple therapeutic indications, the reports should be organized in a separate Section 5.3.5 for each indication. In such cases, if a clinical efficacy study is relevant to only one of the indications included in the application, it should be included in the appropriate Section 5.3.5; if a clinical efficacy study is relevant to multiple indications, the study report should be included in the most appropriate Section 5.3.5 and referenced as necessary in other Sections 5.3.5, e.g., Section 5.3.5A, Section 5.3.5B.

5.3.5.1 Study reports of controlled clinical studies pertinent to the claimed indication

The controlled clinical study reports should be sequenced by type of control:

- Placebo control (could include other control groups, such as an active comparator or other doses)
- No-treatment control
- Dose-response (without placebo)
- Active control (without placebo)
- External (Historical) control, regardless of the control treatment

Within each control type, where relevant to assessment of drug effect, studies should be organized by treatment duration. Studies of indications other than the one proposed in the application, but that provide support for efficacy in the proposed use, should be included in Section 5.3.5.1.

Where a pharmacodynamic study contributes to evidence of efficacy, it should be included in Section 5.3.5.1. The sequence in which studies were conducted is not considered pertinent to their presentation. Thus, placebo-controlled trials, whether early or late, should be placed in Section 5.3.5.1. Controlled safety studies, including studies in conditions that are not the subject of the application, should also be reported in Section 5.3.5.1.

5.3.5.2 Study reports of uncontrolled clinical studies

Study reports of uncontrolled clinical studies (e.g., reports of open label safety studies) should be included in Section 5.3.5.2. This includes studies in conditions that are not the subject of the marketing application.

5.3.5.3 Reports of analyses of data from more than one study

Many clinical issues in an application can be addressed by an analysis considering data from more than one study. The results of such an analysis should generally be summarized in the clinical summary documents, but a detailed description and presentation of the results of such analyses are considered critical to their interpretation. Where the details of the analysis are too extensive to be reported in a summary document, they should be presented in a separate report. Such reports should be placed in Section 5.3.5.3. Examples of reports that would be found in this section include: a report of a formal meta-analysis or extensive exploratory analysis of efficacy to determine an overall estimate of effect size in all patients and/or in specific subpopulations, and a report of an integrated analysis of safety that assesses such factors as the adequacy of the safety database, estimates of event rates, and safety with respect to variables such as dose, demographics, and concomitant medications. A report of a detailed analysis of bridging, considering formal bridging studies, other relevant clinical studies, and other appropriate information (e.g., PK and PD information), should be placed in this section if the analysis is too lengthy for inclusion in the Clinical Summary.

5.3.5.4 Other study reports

This section can include:

- Reports of interim analyses of studies pertinent to the claimed indications
- Reports of controlled safety studies not reported elsewhere
- Reports of controlled or uncontrolled studies not related to the claimed indication
- Published reports of clinical experiences with the medicinal product that are not included in Section 5.3.5.1. However, when literature is important to the demonstration or substantiation of efficacy, it should be included in Section 5.3.5.1
- Reports of ongoing studies

5.3.6 Reports of post-marketing experience

For products that are currently marketed, reports that summarize marketing experience (including all significant safety observations) should be included in Section 5.3.6.

5.3.7 Case report forms and individual patient listings

Case report forms and individual patient data listings that are described as appendices 16.3 and 16.4 in the ICH clinical study report guideline, should be placed in this section when submitted, in the same order as the clinical study reports and indexed by study.

5.4 Literature references

Copies of referenced documents, including important published articles, official meeting minutes, or other regulatory guidance or advice should be provided here. This includes copies of all references cited in the Clinical Overview, and copies of important references cited in the Clinical Summary or in the individual technical reports that were provided in Module 5, section 5.3. Only one copy of each reference should be provided. Copies of references that are not included here should be immediately available on request.

Table 5.1 Listing of Clinical Studies

Type of Study	Study Identifier	Location of Study Report	Objective(s) of the Study	Study Design and Type of Control	Test Product(s); Dosage Regimen; Route of Administration	Number of Subjects	Healthy Subjects or Diagnosis of Patients	Duration of Treatment	Study Status; Type of Report
BA	001	Vol 3, Sec. 1.1, p. 183	Absolute BA IV vs Tablet	Cross-over	Tablet, 50mg single dose, oral, 10 mg IV	20	Healthy Subjects	Single dose	Complete; Abbreviated
BE	002	Vol 4, Sec. 1.2, p. 254	Compare clinical study and to-be-marketed formulation	Cross-over	Two tablet formulations, 50 mg, oral	32	Healthy Subjects	Single dose	Complete; Abbreviated
PK	1010	Vol 6, Sec. 3.3, p. 29	Define PK	Cross-over	Tablet, 50mg single dose, oral	50	Renal Insufficiency	Single dose	Complete; Full
PD	020	Vol 6, Sec. 4.2, p. 147	Bridging study between regions	Randomised placebo-controlled	Tablet, 50mg, multiple dose, oral, every 8 hrs	24 (12 drug, 12 placebo)	Patients with primary hypertension	2 weeks	Ongoing; Interim
Efficacy	035	Vol 10, Sec. 5.1, p. 1286	Long term; Efficacy & Safety; Population PK analysis	Randomised active-controlled	Tablet, 50mg, oral, every 8 hrs	300 (152 test drug, 148 active control)	Patients with primary hypertension	48 weeks	Complete; Full